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ABSTRACT 
 
Background: Colorectal cancer is the third most common cancer and cause of related deaths 
worldwide. Early colorectal cancer diagnosis is vital in reducing incidence and mortality. There 
is a need for the development of non-invasive screening tools for enhancing the detection of 
the disease. Cancer specific peptides are useful cancer targeting agents that can be used to 
specifically improve early detection strategies. Several cancer targeting peptides have been 
identified. Previous work investigated the specific binding of three of these peptides (p.C, p.L 
and p.14) conjugated to quantum dots and were found to bind to colorectal cancer cell lines 
(HT-29 and Caco-2). However, their uptake, localization and biodistribution in an in vitro and 
in vivo colorectal cancer model have not been determined. This is essential in gaining an 
understanding for future diagnostic or therapeutic based applications. Primary Aim:  The aim 
of this study was investigate the localization of three selected peptides p.C, p.L and p.14 
conjugated to gold nanoparticles in an in vitro and in vivo colorectal cancer model using 
HRTEM. Methodology: The AuNP/peptide conjugates were characterized by HRTEM and 
DLS. For in vitro studies; HT-29, Caco-2 and C3A cells were exposed to the AuNP-p.C, AuNP-
p.L and AuNP-p.14, collected and processed for HRTEM to assess targeting and localization. 
For in vivo studies; the establishment of a colorectal cancer model using the AOM/DSS model 
1 and 2 was conducted. Wistar rats were assigned to 6 groups, five experimental and 1 control 
group. Group 1 received AOM/DSS method 1 and was treated with AuNP-p.L. Group 2 and 3 
received AOM/DSS method 2 and were treated with AuNP-p.C and AuNP-p.14. Group 4 and 
5 remained healthy and treated with AuNP-p.C and AuNP-p.14. Group 6 remained healthy 
receiving no nanoparticle treatment. After treatment, rats were sacrificed and tissue was 
processed for HRTEM. Tissue chosen for HRTEM analysis included: Group 1 (inflamed colon, 
rectum, pancreatic and kidney), Group 4 (kidney) and Group 5 (liver). Results: results obtained 
from nanoparticle characterization suggested that nanoparticles were conjugated to their 
respective peptides and were stable in dispersion. For in vitro studies, results suggested no 
AuNP targeting and localization in HT-29 cell lines. For in vivo studies, no colorectal cancer 
tumours were induced. TEM micrographs did not indicate the presence of nanoparticles in 
colon, rectum, pancreatic, kidney and liver tissue. However, AuNPs were found in the kidney 
tissue (group 4). Conclusion: Although the overall objectives were not met, this study provided 
insight into TEM cell preparation and optimization for future nanoparticle cell interaction 
research. This study also demonstrated the absence of AuNPs in healthy tissue and the presence 
of AuNPs in healthy kidney tissue through renal clearance, a favourable quality for diagnostic 
or therapeutic applications 
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CHAPTER ONE: LITERATURE REVIEW 
1.1.General introduction  
 
According to GLOBOCAN 2012, colorectal cancer (CRC) is the third most common and cause 
of cancer-related deaths worldwide (1.4 million, 9.7%), with 746,000 cases in men and 614,000 
cases in woman. High incidence rates were found in Australia, Western, Southern and Northern 
Europe with a low incidence of colorectal cancer found in Africa (except South Africa), South 
America and Asia. In South Africa, colorectal cancer is the fourth most prevalent cancer (5.8%) 
and 6th leading cause of death (6.4%) (Ferlay et al., 2013). 
 
In Africa, 645,000 new cases of cancer and 456,000 deaths have been reported in 2012. This 
comprises 4.5% of the global cancer incidence and 5.6% of the global cancer mortality rate 
(Ferlay et al., 2013). These rates are expected to double in 2030 due the aging, growth of the 
population and increase in the western lifestyle (Jemal et al., 2012). Although the cancer burden 
in Africa appears to be very low, there is a possibility that this is not the true reflection for 
reasons that high-quality population-based cancer registries are not commonly available 
(Ferlay et al., 2010). As an example, in South Africa, the last national cancer registry report 
made available has been in 2007 (CANSA., 2014 ). Colon carcinogenesis is a disease that 
requires years to develop, providing ample time for diagnosis and treatment. Unfortunately, it 
is common for majority of colonic tumours to go undetected until the cancer has progressed 
into a late stage where the tumour has metastasized (Kelly & Jones, 2003). In most parts of 
Africa, early detection and treatment services are limited. Conventional screening through 
colonoscopy is not only costly but not supported by the existing health care facilities whilst 
faecal occult blood tests (FOBTs) lack the needed sensitivity. Hence, there is a crucial need for 
the development of better diagnostic systems for colorectal cancer detection. The past decade 
has seen an explosion in our understanding of the cellular and molecular events in colorectal 
cancer. The identification of disease biomarkers and molecules (peptides, aptamers, antibodies, 
etc.) that can recognise these biomarkers specifically aims to improve early detection strategies 
through specific targeting. Together with nanotechnology, this creates a powerful diagnostics 
platform.  
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Previous studies have established the binding properties of three known phage display peptides 
(Shadidi & Sioud, 2003; Wang et al., 2012; Wu et al., 2000). Through fluorescence studies 
previously investigated by Mazyambe (2013) the interaction of these peptides towards 
colorectal cancer cell lines has been established. Much remains to be elucidated specifically on 
their cell uptake, localization and biodistribution in an in vitro and in vivo model. This is 
essential in gaining an understanding for future diagnostic or therapeutic based applications. 
1.2.Background to colorectal cancer 
 
Cancer is the term used for a disease in which abnormal cells in the human body start dividing 
and growing without control. CRC is a type of cancer that starts in the colon and rectum of the 
large intestine. It is a disease which has a long pre-malignant and asymptomatic development. 
Most CRCs starts with polyps occurring on the epithelial lining of the colon and rectum. These 
polyps may be benign (e.g. non-neoplastic), neoplastic polyps (e.g. adenomas, adenomatous) 
and cancers (Bardhan & Liu, 2013). CRC can be classified further into three observed 
populations; sporadic, inherited or familial (Johns & Houlston, 2001; Rustgi, 2007). In majority 
of cases, CRC occurs sporadically, whilst 3-4% of CRC cases are attributed to inherited 
mutations and 20-30% of patients reveal a family history of the disease (Johns & Houlston, 
2001; Rustgi, 2007). 
1.3.The structure and function of the large intestine 
 
The large intestine forms a part of the digestive system and can be divided into three parts; the 
proximal (cecum, ascending colon and transverse colon), distal/left colon (descending colon, 
sigmoid colon) and the rectum (Fredericks, 2013). This system functions in processing food 
for energy and removes the solid waste as faecal matter (Fredericks, 2013; Keshav & Bailey, 
2012). In addition to these functions, it is inhabited by a variety of commensal microbes aiding 
in colon physiology homeostasis. The colon consists of four basic layers - mucosa, submucosa, 
muscularis externa (longitudinal and circular) and the serosa, as seen in Figure 1.1. The mucous 
membrane forming the inner lining of the large intestine lack villi and contains numerous crypts 
composed of vast amounts of goblet cells, enterocytes and a few enteroendocrine cells. 
Covering this layer is the submucosa consisting of connective tissue embedded with large 
blood, nerve and lymphatic vessels. This extends to the muscularis externa an area consisting 
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of longitudinal and circular muscle. The outmost layer serosa consists of several layers of 
connective tissue. 
 
Figure 1.1: The anatomy of the large intestine (Encyclopaedia-Britannica.Inc, 2003). 
1.4.Molecular bases of colorectal carcinogenesis 
 
In 1990, Fearon and Vogelstein originally proposed the adenoma-carcinoma model describing 
colorectal carcinogenesis as a step-wise progression of genetic mutations (Fearon & 
Vogelstein, 1990). The altered genes include adenomatous polyposis coli (APC), tumour 
protein p53 ( TP53 or p53),  Kirstin ras (KRAS), chromosome 18 (i.e. this includes the deleted 
in colon cancer (DCC) and mothers against decapentaplege homolog (SMAD), as seen in 
Figure 1.2. These subsequent alterations perturb conserved signalling pathways which regulate 
cellular metabolism, differentiation, proliferation and survival. Ultimately transforming normal 
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epithelial cells to benign adenomas and malignant carcinomas (Chung, 2000; Fearon & 
Vogelstein, 1990). 
 
Figure 1.2: The adenoma-carcinoma sequence on colorectal cancer and the associated molecular mutations 
(Fodde, 2002). 
1.4.1. APC/β-catenin and Wnt signalling pathway 
 
Approximately 70-80% of sporadic adenomacarcinomas have somatic mutations of the APC 
gene. The APC gene is a tumour suppressor gene located on chromosome 5q21. It encodes a 
multifunctional protein with a molecular weight of ~310 kD, containing domains that interact 
with a scaffold protein Axin, β-catenin and serine-threonine glycogen synthase-3β (GSK-3β). 
(Fearon, 2011; Fodde, 2002). The APC gene product may regulate cell-cell adhesion, cell 
migration, apoptosis and cell regulation. However, its major role has been to participate in the 
formation of a multi-protein complex that’s joins to β-catenin, causing its phosphorylation, 
subsequent ubiquitination and degradation of the β-catenin an essential component in the Wnt 
signalling pathway(Sameer, 2013). The loss of APC function disrupts β-catenin destruction 
resulting in the intracellular accumulation of active β-catenin in the cytoplasm. The β-catenin 
complexes with DNA-binding proteins resulting in its translocation to the nucleus where it 
begins to function as a transcriptional co-activator to various cell proliferation genes (Fearon, 
2011; Sameer, 2013). Activating mutations in the β-catenin gene (CTNNB1) have also been 
observed in colorectal neoplasia (Morin et al., 1997).  
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These APC mutations were first observed by familial adenomatous polyposis (FAP) an 
autosomal dominant disease (Leslie et al., 2002).. FAP is caused by a germ-line mutation of 
APC gene leading to the development of hundreds of intestinal polyps at a relatively young 
age. If left untreated, 100% of individuals with the mutation will develop colorectal cancer  
1.4.2. KRAS oncogene and the EGFR signalling pathway 
 
KRAS gene is a proto-oncogene located on chromosome 12p12, encoding a ras protein with a 
molecular weight of 21kD (Fearon, 2011; Tan & Du, 2012). It is a guanosine-5’-triphosphate 
(GTP) binding protein with GTPase activity. When bound to GTP, the ras protein is active but 
becomes inactive when GTP is hydrolysed to guanosine diphosphate (GDP). Mutations of the 
KRAS gene occur in approximately 35-45% of CRCs. The ras protein is a downstream effector 
of the epidermal growth factor receptor (EGFR) that signals through the Braf protein and in 
turn, activates the MAPK pathway which is responsible for  cellular proliferation and 
differentiation pathways.  
1.4.3.  p53 gene  
 
The tumour suppressor p53 gene is located on the short (p) arm of chromosome 17. It encodes 
a 393 amino acid transcription factor responsible for maintaining genomic integrity by inducing 
cell cycle arrest or apoptosis when DNA is damaged. Mutations of p53 appear late in the 
adenoma-carcinoma sequence and are found in almost half of all colorectal cancer cases 
(Chung, 2000; Pritchard & Grady, 2010).  
1.4.4. Chromosome 18q21 and TGF- β pathway 
 
The allelic loss located on chromosome 18q has been identified in approximately 70% of 
colorectal tumours at more advanced stages of the tumourogenesis (Leslie et al., 2002). It was 
initially thought that the tumour suppressor gene in this region was the “deleted in colorectal 
carcinoma” (DCC) gene, however the product of this gene was a cell surface receptor for 
neuronal protein netrin-1 (Keino-Masu et al., 1996). Other tumour suppressor genes located on 
18q region were also identified; these include the SMAD2 and SMAD4. The transcriptional 
products of both genes are involved in the transforming growth factor-β-(TGF-β) pathway 
(Chung, 2000; Fearon, 2011). In the TGF-β signalling pathway, signals through the TGFβ-cell 
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surface receptors leads to the phosphorylation of SMAD2 and SMAD3 proteins in mammalian 
cells. The SMAD2/3 protein complex enters the nucleus where they join to SMAD4. This 
protein complex then proceeds to regulate genes involved in the regulation of cell growth 
differentiation and apoptosis. Cable proteins, located on chromosome 18q11.2-12.1, have been 
marked as a relevent tumour suppressor gene. These proteins act as a linker protein facilitating 
the increase in tyrosine phosphorylation of cyclin-dependent kinases such as cdk2. The loss of 
cable expression has been shown to occur in 60-70% of sporadic colorectal cancers (Chung, 
2000; Kirley et al., 2005). 
1.5.Colorectal cancer pathogenesis 
 
Since the introduction of the adenoma-carcinoma model, knowledge of CRC development has 
advanced considerably. It is well known and reported that CRC arises as a result of the 
accumulation of genetic, epigenetic and DNA match repair gene mutations (Chung, 2000; 
Fearon & Vogelstein, 1990). The loss of genomic and epigenomic stability are the phenotypic 
features of colorectal carcinogenesis. Genomic instability has been observed by two pathways; 
these include the chromosomal instability (CIN) and microsatellite instability (MSI) pathway. 
Epigenetic instability in sporadic CRC have been demonstrated by the CpG island methylator 
phenotype (CIMP) pathway (Bardhan & Liu, 2013). 
1.5.1. Chromosomal instability (CIN) pathway 
 
Genomic instability has emerged as the fundamental process in colorectal carcinogenesis. The 
most common type of genomic instability is the CIN pathway also known as the adenoma-
carcinoma sequence which accounts for approximately 60-70% of all CRC cases (Pancione et 
al., 2012; Pino & Chung, 2010). The development of CIN tumours follows the predictable 
progression of mutations in oncogenes and tumour suppressor genes such as APC, TP53, 
KRAS, phosphoinositide 3-kinase (PI3KCA), SMAD4 and loss of heterozygosity (LOH) as 
seen in Figure 1.2 (Fodde, 2002). CIN tumours are characterized as having an imbalance of 
chromosome numbers (aneuploidy) and loss of heterozygosity. These tumours are 
predominantly found in the right (distal) colon (Cardoso et al., 2007; Rosner & Strul, 2014). 
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1.5.2. Microsatellite instability (MSI) pathway  
 
The inactivation of the mismatch repair mechanism (MMR) may result in genomic and 
epigenomic instability. The MMR mechanism corrects errors that spontaneously occur as a 
result of DNA damage, oxidative stress or following DNA replication errors (Armaghany et 
al., 2012). Microsatellites are short repetitive DNA nucleotide sequences prone to frame shift 
mutations and base-pair substitutions during replication. If the MMR system is deficient within 
the cell, this creates microsatellite instability. Unlike the CIN pathway, this pathway is 
relatively well understood, near-diploid and are predominantly found in the left (proximal) 
colon (Cardoso et al., 2007). This pathway accounts for 15% of all CRC, 5% being Lynch 
syndrome or hereditary non-polyposis colorectal cancer syndrome (HNPCC) (Pritchard & 
Grady, 2010). Individuals with Lynch syndrome present germline mutations in the MMR 
genes. Ninety percent of all Lynch syndrome cases occur from mutations in one or two major 
genes, MutL homolog 2 (MSH2) and MutS homolog 1 (MLH1) (Goel & Boland, 2010). The 
remaining 10% of cases arise from mutations in the other MMR genes; MutS homolog 6 
(MSH6), postmeiotic segregation 2 (PMS2) and MutL homolog 3 (MLH3).  
1.5.3. CpG island methylator phenotype (CIMP) pathway 
 
The CpG (cytosine preceding guanosine) island methylator phenotype (CIMP) pathway is the 
third pathway to the development of sporadic colorectal cancer and accounts for approximately 
12-25% of CRCs (Pitule et al., 2013). The CIMP pathway creates epigenomic instability 
characterized both by hypermethylation of promoters that contain CpG islands and global DNA 
hypomethylation (Pancione et al., 2012; Pritchard & Grady, 2010). More than 50% of human 
genes have been shown to be regulated by promoters containing CpG islands. However, in 
CRC, CpG islands have been shown to be hypermethylated resulting in the silencing of tumour 
suppressor genes. In contrast to CIN tumours, CIMP tumours show less aneuploidy and 
frequently develop within the left (proximal) colon (Venkatachalam et al., 2010). CIMP 
tumours have been associated with BRAF and KRAS mutations through the MAPK pathway 
however CIMP tumours arise from serrated  rather than adenomatous polyps.  
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1.6.Animal model for colorectal carcinogenesis  
 
There exist several experimental models for the investigation of colon carcinogenesis; these 
can be divided into colorectal cancer cell lines or animal models (Robertis et al., 2011). Animal 
models are important tools, providing us with a larger insight into the pathogenesis of CRC, 
but also advancing our understanding of therapeutic and diagnostic strategies (Ravnik-Glavač 
et al., 2000; Robertis et al., 2011). The ultimate goal of modelling CRC in animal models is to 
recapitulate the disease as seen in humans. Johnson and Fleet (2013) describe three 
characteristics essential to maintaining this goal. First, the cancer should only be situated in the 
large intestine where the disease is predominantly seen in humans. Secondly, the colonic 
lesions should represent the histological and molecular features of human CRC and thirdly, the 
model should capture the complex cellular interactions that are relevant to human colon cancer. 
The CRC animal models can broadly be divided into spontaneous intestinal cancers, 
chemically/environmentally-induced or genetically modified rodents (Johnson & Fleet, 2013). 
Carcinogen–induced colorectal cancer has shown to be superior to all animal models as CRC 
pathogenesis occurs sporadically and undergo similar molecular alterations found in human 
colorectal carcinogenesis (Robertis et al., 2011; Rosenberg et al., 2009). These models are 
highly reproducible and can be readily tested on animals with different genetic backgrounds.  
1.6.1. Dimethylhydrazine and Azoxymethane 
 
Dimethylhydrazine (DMH) and its metabolite, Azoxymethane (AOM), are the two most 
commonly used carcinogens to induce CRC in rodents. This is a less expensive, more potent 
and convenient model to use with majority of tumours developing within the distal colon, with 
a low frequency within the small intestine (Rosenberg et al., 2009). DMH is metabolically 
activated to DNA-reactive products by multiple xenobiotic-metabolizing enzymes (Druckrey, 
1970; Fiala, 1977; Rosenberg et al., 2009). This produces intermediates, AOM and 
methylazoxymethanol (MAM) which can be transported to the colon or enter the enterocytes 
from blood circulation, as seen in  Figure 1.3. MAM is unstable, and readily yields the mutagen 
methyldiazonium ion either spontaneously or through alcohol dehydrogenases. This product is 
capable of altering the information of DNA through methylation but also modifying histones 
and DNA-binding proteins (Fiala, 1977; Perše & Cerar, 2005). The majority of DMH/AOM 
tumours harbour β-catenin and K-RAS mutations, with elevated levels of COX‐2 and inducible 
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nitric oxide synthase (iNOS‐2) similar to the genetic and molecular alterations in sporadic 
human colorectal carcinogenesis (Takahashi et al., 2000; Yoshimi et al., 2009).  
 
In 1973 DMH-induced colon cancer was seen as an effective experimental model for sporadic 
CRC. DMH was administrated with weekly subcutaneous injections for 7 months. This resulted 
in  rats developing intestinal tumours similar to human colorectal adenomas (Martin et al., 
1973). Later studies done by Deschner and Long (1977) have shown the reduction of 
subcutaneous injections to 6 injections over a period of 7 months resulted in neoplasms found 
in 83% of the mice (Deschner & Long, 1977). An increasing number of studies, however, 
switched to the AOM as it offers several advantages over DMH. This includes enhanced 
potency, greater stability in a dosing solution, and higher reproducibility (Rosenberg et al., 
2009). When using single or multiple injections of DMH/AOM, colon tumour development 
have shown a low tumour incidence and long latency period of 7 to 8 months (Neufert et al., 
2007; Tanaka et al., 2003). However, with the subsequent treatment using dextran sulphate 
sodium (DSS), tumour development could take as little as 7-10 weeks (Thaker et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 3: The metabolism of DMH and AOM (Rosenberg et al., 2009). 
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1.6.2. Dextran sulphate sodium 
 
Dextran sulphate sodium (DSS) is a non-genotoxic sulphated polysaccharide used to induce 
colitis (inflammation to the epithelial lining of the colon) when administrated through diet or 
drinking water (Suzuki et al., 2005). Through DSS administration, colonic inflammation could 
resemble that of inflammatory bowel disease or ulcerative colitis. With a long term 
administration, colonic malignancies are induced which resemble the adenoma-carcinoma 
sequence as discussed in section 1.4. According to Perše and Cerar (2012) the tumour 
promoting effects of DSS is dependent on various factors which include the administration 
dose, duration, molecular weight, the batch, manufacturer and genetic susceptibility of rodent 
(strain, substrain and gender) (Perše & Cerar, 2012). It is also suspected that microbial factors 
could play a role. According to Suzuki et al. (2005), the tumour promoting effect of DSS 
(molecular weight of 40 kDa) is strongly related to the administration dose. The literature 
suggests that the exposure to DSS in drinking water at a dose of 1% to 2% DSS for 1 week 
after a single injection of AOM (10 mg/kg body weight) could produce multiple colonic 
neoplasms within 20 weeks compared with mice treated with AOM and given lower doses (0.5, 
0.25 and 0.1% w/v DSS). This suggests that at a higher DSS dose, severe inflammation 
contributes to the tumour promoting effects in rodents. No such study has looked at the dose-
dependent promoting effects of different DSS molecular weights. 
 
1.6.3. AOM/DSS- induced carcinogenesis model 
 
Taking into consideration the long term experimental period needed to induce colonic tumours 
using AOM (tumour-inducing agent) or DSS (tumour-promoting) alone, the AOM/DSS 
method was developed to dramatically increase tumour development to as little as a few weeks 
(Tanaka et al., 2003). The AOM/DSS treated rodent model is also applicable when the study 
is focused on tumour development as a result from ulcerative colitis or crohns disease. 
Historically, colon carcinogenesis studies have been carried out in rats. However, murine 
models holds an advantage due to availability of extensive genetic information on individual 
mouse lines (Robertis et al., 2011; Thaker et al., 2012). The AOM/DSS rodent model has been 
proven to be highly valuable for its ability to produce tumours mirroring the various 
pathological aspects of human CRC and for investigating novel diagnostic, prognostic or 
chemotherapeutic agents against CRC (Robertis et al., 2011). 
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1.7. Colorectal cancer screening tools  
 
Research has indicated that patients presenting stage I or II of CRC disease have a 5 year 
survival rate of 93.2% and 82.5% respectfully, when treated with surgery or when surgary is 
combined with chemotherapy (Bianchi et al., 2011). CRC survival rates are drastically reduced 
at later stages of the disease with patients having a 59.5% and an 8.1% survival rate of stage 
III and IV disease (O’Connell et al., 2004). Although survival is strongly linked to the stage of 
CRC diagnosis (Coetzee, 2013; García-Bilbao et al., 2012). However; early diagnosis of CRC 
becomes difficult as CRC symptoms only appear are common in advanced stages where lesions 
are often higher grade and incurable (Kanthan et al., 2011). Randomized trials suggest that 
early detection of cancer through screening has proven to reduce CRC mortality (Hardcastle et 
al., 1996; Kronborg et al., 1996; Scholefield et al., 2002). However, there are several pitfalls 
to the screening tools available. The current CRC screening tools in practise are endoscopic 
and the biomarker screening.  
1.7.1. Endoscopic screening 
 
Colonoscopy is currently considered the “gold standard” (Kanthan et al., 2011). It is a tool used 
to visualize the mucosa wall of the colon, remove pre-malignant lesions, malignant tumours or 
adenomas up to 100% (Coetzee, 2013). Despite its high reliability this technique has several 
limitations. Colonoscopy is an invasive tool requiring sedation and full bowel preparation 
(Baxter & Rabeneck, 2008; Rex et al., 1997). It can be costly and requires experienced 
physicians. Consequently, it lacks patient compliance. Colonoscopy examination also presents 
a miss rate of adenomas by 24% as visualization of the full length of the colon cannot be seen 
(Rex et al., 1997). This miss rate also increases up to 27% for flat and depressed adenomas 
smaller than 5 mm. Except for one case controlled study showing  a reduction of 67%  in 
mortality only for left-sided  colorectal cancer (Baxter & Rabeneck, 2008), there are currently 
no other randomized control trials available to draw conclusions as to whether this technique 
reduces CRC mortality. 
 
Flexible sigmoidoscopy is a tool less invasive than colonoscopy. It is based on the visualization 
of the mucosa of the left colon with tissue biopsy (Coetzee, 2013). This technique does not 
require the use of trained physicians which consequently lowers the cost of examination. 
Randomized controlled trials have shown that screening programmes using flexible 
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sigmoidoscopy reduced mortality by detecting early CRC lesions and advanced adenomas 
(Baxter et al., 2009; Kronborg et al., 1996; Littlejohn et al., 2012). However, this detection 
tool is limited as adenomas proximal to the colon may be missed. 
1.7.2. Biomarker screening 
 
Biomarkers are indicators of a biological state. These biomarkers can be used as a diagnostic 
tool or to study the normal, pathogenic or pharmacological processes (Tanaka et al., 2010). At 
present, the faecal occult blood test (FOBT) is the widely used fecal marker for CRC screening 
(Tanaka et al., 2010). FOBT is based on rectal bleeding associated with CRC, detecting 
haemoglobin enzymatically or immunologically in the stool(Kanthan et al., 2011). The 
advantage of this method is its relative low cost, tests simplicity, safety, and non-invasiveness. 
Through randomized controlled trials conducted by Littlejohn et al. (2012), FOBT has shown 
to reduce CRC mortality by 21%. However, the FOBT is limited as the sensitivity for the 
detection of pre-cancerous lessions (~ 30%) and CRCs (40-85%) are low (Kanthan et al., 2011; 
Tanaka et al., 2010). This detection tool may falsely react to heme in red meat or detect 
bleeding from the stomach or small bowel, frequently reporting false-positive and false-
negative results. 
 
The increase in genomics and proteomics contributed to our molecular understanding of CRC 
(García-Bilbao et al. (2012).This has helped identify genes and/or proteins that would aid in 
the early detection of CRC. To our knowledge such markers are currently being used or have 
yet to be clinically validated. See Table 1. (Tanaka et al., 2010). 
 
Serum biomarkers such as CEA and CA 19-9 are in clinical use for disease state evaluation, 
but are often unemployed for screening purposes due to lack in sensitivity and specificity where 
they show an overlap with other disease such as hepatisis, inflammatory bowel disease or 
pancreatisis. Other serum based markers are have insuffecient evidence for routine use whilst 
genetic markers are not wideley used in clinical settings. Other biomarkers remain promising 
but still need to be clinically validated (García-Bilbao et al., 2012; Tanaka et al., 2010).  
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Table 1: Molecular biomarkers for the detection of CRC (Tanaka et al., 2010). 
Colorectal Cancer Biomarkers Subject  Type  Status  
Faecal haemoglobin  Stool  Protein  IU  
K-ras  Stool  DNA  CV  
APC  Stool  DNA  CV  
L-DNA  Stool  DNA  CV  
p53  Stool  DNA  CV  
CEA  Serum  Protein  IU  
CA19.9  Serum  Carbohydrate  IU  
TIMP-1  Serum  Protein  CV  
Spondin-2, DcR3, Trail-R2, Reg IV, MIC 1  Serum  Protein  PD  
PSME3  Serum  Protein  PD  
NNMT  Serum  Protein  PD  
CRMP-2  Serum  Protein  PD  
SELDI (apolipoprotein C1, C3a-desArg, alpha1-
antitrypsin, transferrin)  
Serum  Protein  PD  
HNP 1-3  Serum  Protein  PD  
MIF  Serum  Protein  PD  
M-CSF  Serum  Protein  PD  
M2-PK  Serum  Protein  PD  
Prolactin  Serum  Protein  PD  
Septin 9  Plasma  DNA  PD  
Five-gene panel (CDA, BANK1, BCNP1, MS4A1, 
MGC20553)  
WBC  DNA  PD  
CCSA-2, -3 -4  Serum  Protein  PD  
MMP-9, -7  Serum  Protein  PD  
Laminin  Serum  Protein  PD  
IU: in use, CV: clinical validation, PD: preclinical development 
 
An ideal screening technique requires a combination of early-stage cancer detection, high 
sensitivity and specificity, affordability, non-invasiveness, safety, wide scale applicability and 
a high patient compliance (Coetzee, 2013; Kanthan et al., 2011). These current screening tools 
(colonoscopy, flexible sigmoidoscopy and FOBT) do not meet this standard (Tanaka et al., 
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2010). Consequently there is a need for the development of novel non-invasive biomarkers 
capable of enhancing the early detection of the disease.  
1.8.Colorectal cancer targeting peptides 
1.8.1. Why peptides? 
 
Biomarkers can exist as  antibodies, peptides, nucleic acid or others such as carbohydrates or 
vitamins (Ladner et al., 2004; Yu et al., 2012). Antibodies are the popular and conventional 
candidates for tumour recognition and drug delivery. They are assumed to have high specificity 
and affinity, large-reproducibility, acceptable toxicity, predictability, a favourable cost and low 
antigenicity (Ladner et al., 2004; Patri et al., 2004; Sapra & Allen, 2002). However, there are 
several limitations which include; their large size which restricts passage through the 
endothelial cell membrane capillaries resulting in poor delivery to tumours and their difficulty 
in conjugating the antibodies to delivery carriers e.g. nanoparticles (Yu et al., 2012). 
Serum biomarkers such as CEA and CA 19-9 (Table 1) are in clinical use for disease state 
evaluation, but are often unemployed for screening purposes due to lack in sensitivity and 
specificity where they show an overlap with other disease such as hepatitis, inflammatory 
bowel disease or pancreatitis. Other serum based markers have insufficient evidence for routine 
use whilst genetic markers are not widely used in clinical settings. Other biomarkers remain 
promising but still need to be clinically validated (García-Bilbao et al., 2012; Tanaka et al., 
2010).  
Peptides on the other hand have been receiving greater attention due to their small size, better 
tumour penetration, selective binding and their ability to evade the immune system unlike 
antibodies.  
1.8.2. The identification of cancer specific peptides 
 
Combinatorial peptide library technology have made it possible to identify peptides possessing 
binding specificity for tumour receptors, enzymes or antibodies (Shadidi & Sioud, 
2003).Numerous specific peptides have been identified specifically p.C, p.14 and p.L which 
will be discussed in detail.  
Due to a confidential agreement, the sequences of the peptides are not mentioned here. 
15 
 
p.C was discovered by Wu et al. (2000) using random phage display and was raised against 
prostate specific antigen. This study showed that this particular peptide bound specifically 
towards prostate cancer cells. However; Mazyambe (2013)  has demonstrated the specific 
binding of this peptide towards cancer cell lines not of prostate cancer origin. In Mazyambe 
(2013) study, p.C has demonstrated to bind to Caco-2 and HT29 (colorectal cancer cell lines) 
with high specificity compared to other cell lines. This study reported that p.C peptide was 
unable to bind to a non-cancerous cell line and can thus be used to differentiate between 
cancerous and non-cancerous tissue (Mazyambe, 2013) 
 
p. L was discovered by Shadidi and Sioud (2003) using random phage display. The study 
showed that p.L was capable of preferential binding and internalization into breast cancer cell 
lines. However; this peptide was re-tested and showed strong binding towards glioma cell line 
BT4C (Shadidi & Sioud, 2003). Another study has shown that the p.L peptide has a binding 
specificity towards cancer cells that over express the ErbB-2 growth factor receptor (Wang et 
al., 2007). Mazyambe (2013) has demonstrated the specific binding of this peptide towards 
HT29 colorectal cancer cells compared to Caco-2, Hela, HepG2 and Kmst-6 cell lines.  
 
Wang et al. (2012) discovered five colorectal binding peptides from a random phage display 
library. p.14 was specifically analysed using immunofluorescence. Results indicated that this 
peptide was able to bind more favourable to LoVo cells than to normal human colon mucous 
epithelium (NHCME) cells.  The study by Wang et al. (2012) recommended that a colorectal 
animal model should be used to evaluate the binding specificity of this peptide and to the best 
of our knowledge such a study not yet done. 
1.9.Nanotechnology based- delivery systems 
 
Nanotechnology is defined as the controlled manipulation of devices at one billionth of a metre 
(10-9 M). The concept of nanotechnology was first introduced by Richard Feyman. In his letter 
titled “There is plenty of room at the bottom”, Feyman wrote that properties of material at an 
atomic scale differ considerably to material at their bulk scale, as they are governed by the law 
of quantum mechanics (Feynman, 1960). These unique physicochemical properties include an 
increased surface area, increased chemical reactivity, novel optical, magnetic and thermal 
properties (Jain et al., 2007; Sahoo et al., 2007). A large focus has been placed on cancer 
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nanotechnology specifically on the development of novel diagnostic, therapeutic and 
monitoring tools. Nanoparticles are similar in size to that of biomolecules such as proteins (1-
200nm), DNA (~2 nm) and the cell membrane (6-10 nm), see figure 1.4 (Patra et al., 2010). 
This makes nanoparticles capable of overcoming biological barriers such capillary vessels and 
preferentially accumulating in tumours (Cai et al., 2008; Wang & Thanou, 2010).  
 
 
 
Figure 1.4: A comparison between the sizes of nanoparticle and other molecules (McNeil, 2005). 
 
1.9.1. Gold nanoparticles   
 
The use of colloidal gold for medicinal and decorative purposes is dating back to 2500 BC. 
Historically, alchemists would make Aurum portable (drinking gold) for the treatment of 
fevers, syphilis or epilepsy. In 1927, colloidal gold was shown to possess healing properties 
and was used for the treatment of rheumatoid arthritis (Antonovych, 1981; Higby, 1982; 
Thakor et al., 2011). Today the use of gold nanoparticles (AuNPs) has expanded in biomedical 
research. Due to their unique properties they are used in diagnostic, therapeutic or theranostic 
applications (Patra et al., 2010). 
 
Gold nanoparticles can  easily be synthesized in a variety of shapes (spheres, rods, tubes, wires, 
cubic, hexagonal, triangular) and sizes (5-200 nm) due to controlled changes in chemical 
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reaction parameters (Patra et al., 2010). The most common method of gold nanoparticle 
synthesis is through chemical reduction of gold (III). This is an economically cheap, safe and 
reliable method, first reported Turkevich et al. (1951) and later improved by Frens (1973) and 
Kimling et al. (2006). In this method gold nanospheres are created by the addition of 
trisodiumcitrate to a heated aqueous solution of tetrachloroauric acid. This results in the 
nucleation of gold ions which are then stabilized by the remaining citrate molecules forming a 
negative AuNP surface charge (Zhao et al., 2013). The negative surface charge increases 
reactivity of AuNPs, allowing for surface functionalization of biomolecules (peptides, DNA, 
antibodies, etc.). 
1.9.1.1.Gold nanoparticle optical properties  
 
Gold nanoparticles have attracted considerable attention due to their unique optical properties. 
Gold in bulk is seen as a familiar yellow colour, however with the reduction in size and 
dimensionality of gold, a drastic change occurs in the electronic properties due to the reduction 
in spatial length of electron motion (El-Brolossy et al., 2008). When incident light interacts 
with the free d electron  on the surface of Au core, this creates a collective coherent oscillation 
of electrons across the surface of the nanoparticles known as surface plasmon resonance (SPR), 
as seen in Figure 1.5 (Willets & Van Duyne, 2007). The surface plasmon oscillation of the 
metal electrons results in a strong enhancement of absorption and scattering of light (Sokolov 
et al., 2003). 
Gold nanoparticles can be seen as a contrast agent in cellular and biological imaging 
applications. Contrast agents greatly increase the sensitivity of an imaging technique, this 
allows us to visualize previously undetected abnormalities in cells or tissue of interest. The 
current contrast agents include flourometric, chemiluminescent or colorimetric techniques. 
These probes often suffer from weak optical signals and photobleaching. Gold nanoparticles 
have become an alternative consideration due to their SPR, non-photobleaching and non-
cytotoxicity properties (Jain et al., 2007). 
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Figure 1.5: Schematic diagrams illustrating localized surface plasmon resonance (Willets & Van Duyne, 2007). 
 
Taking advantage of gold nanoparticles absorption properties, gold nanoparticles have been 
used as a contrast agent in photoacoustic imaging (Mallidi et al., 2009). Whilst, El-Sayed et al. 
(2006) has demonstrated the difference between cancerous and non-cancerous cells through 
dark-field microscopy and absorption spectroscopy. Luo et al. (2010) has demonstrated the 
ability to create a new multiplexing detection scheme using differential interference contrast 
microscopy. Similarly, Sokolov et al. (2003) have has exploited the strong light scattering of 
gold nanoparticles for real-time optical imaging of pre-cancer and cancers by using confocal 
reflectance microscopy. In addition to this, gold nanoparticles have a high X-ray attenuation 
factor. They have been widely used for labelling and staining of biological specimens for 
electron microscopy (D'amico & Skarmoutsou, 2008; Liou et al., 1996; Mayhew, 2009) which 
will be discussed later in detail. 
1.9.1.2.Gold Nanoparticle in vivo diagnostic applications 
 
The unique properties and the use of gold for the treatment of human disease (e.g. rheumatoid 
arthritis) have made gold nanoparticle an attractive agent for in vivo diagnostic applications. 
As discussed above, gold nanoparticles have been used as contrast agents in in vitro based 
applications based on their ability to scatter visible light. One of the greatest limitations in in 
vivo diagnostics is the non-invasive early detection of cancer. Standard clinical imaging 
technologies such as MRI, CT, X-ray and PET are becoming routinely used in hospitals (Gu, 
2011; Popovtzer et al., 2008). These tools provide us with anatomical information of the body 
through the use of contrast agents which assist in providing greater sensitivity. These tools are 
structural imaging modalities as opposed to molecular imaging modalities as they identify 
tumour location, size and spread. They are not efficient in distinguishing between benign and 
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cancerous tumours or the detection of tumours less than 0.5 cm. As demonstrated by Reuveni 
et al. (2011), gold nanoparticles have a high X-ray attenuation coefficient in comparison to the 
conventional contrast agents such as iodine. By conjugating a targeting molecule (antibody, 
peptide, aptamers, etc.) to gold nanoparticles, gold nanoparticles demonstrate specific targeting 
towards cancer receptors in tumours through an active targeting mechanism as opposed to the 
passive targeting which deals with the enhanced permeability and retention effect (EPR) 
(Arvizo et al., 2011). In this way, active tumour identification and the strong attenuation of 
gold provide an increased tumour specificity and sensitivity. This will provide practitioners a 
non-invasive CT imaging tool which can facilitate the early detection of cancer based on 
specific biomarkers rather than on anatomical structures (Reuveni et al., 2011). 
1.10. The uptake and distribution of gold nanoparticles 
 
In order for nanoparticles to be taken into cells and their subcellular structures, nanoparticles 
must be able to cross the plasma membrane. Polar or charged biomolecules such as amino 
acids, glucose, proteins etc. require active transport via endocytosis pathways or specific 
transporters. Nanoparticles exist in the 1-100 nm size range, similar to the size of biomolecules 
(Kettiger et al., 2013). Experimental studies have revealed that nanoparticles are taken up in a 
similar way than biomolecules, depending on their size (Chithrani et al., 2006; Mironava et al., 
2010; Sonavane et al., 2008), shape (Chithrani et al., 2006), chemical composition (Kulkarni 
& Feng, 2013; Raschke et al., 2004) and surface functionality (Chanda et al., 2010; Li et al., 
2009; Lund et al., 2011; Shi et al., 2012). An additional factor is protein absorption onto the 
surface of the nanoparticle forming a protein corona and this changes  the physicochemical 
properties of the nanoparticles which could affect the rate of cell uptake (Shi et al., 2012). 
Chithrani et al. (2006) has investigated the intracellular uptake of 14, 30, 50, 74, and 100 nm 
spherical and rod shaped gold nanoparticles. Their findings from this study suggested that 
spherical nanoparticles have a higher probability of entering the cells in comparison to rod 
nanoparticles. Results have indicated that nanoparticles with a diameter of 50 nm are most 
efficiently internalized by cells than nanoparticles between 30 -50 nm which are subsequently 
taken up by receptor- mediated endocytosis (Chithrani et al., 2006). Their results also suggest 
that non-specific absorption of serum proteins could play a role in mediating the intracellular 
mechanism and uptake of the nanoparticles. Unbound citrate-stabilized gold nanoparticles have 
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shown greater uptake compared  against protein absorbed nanoparticles as they  compete for 
receptor sites (Chithrani et al., 2006), as seen in Figure 1.6. 
 
Figure 1.6: Known cellular uptake pathways of nanoparticle (Kettiger et al., 2013). 
 
The endocytic pathways can be classified into phagocytosis and pinocytosis. Phagocytosis is a 
process whereby cells of the immune system such as macrophages, monocytes and neutrophils 
internalize nanoparticles larger than 500 nm (Kettiger et al., 2013). Small molecules ranging 
from few to several nanometres are generally taken up in almost all cells by pinocytosis. 
Pinocytosis can be further classified into (i) macropinocytosis (ii) absorptive pinocytosis and 
mainly (iii) receptor-mediated endocytosis. Receptor mediated endocytosis occurs 
predominantly via clathrin-mediated endocytosis (CME) or caveolae-mediated endocytosis 
(CvME), as seen in Figure 1.6 (Chithrani et al., 2006; Kettiger et al., 2013; Treuel et al., 2013). 
Endocytosis transports nanoparticles into cells within vesicles. Depending on their mode of 
internalization, nanoparticles can be subjected to endosomal/lysosomal pathways, as seen in 
Figure 1.7. Intracellular vesicles can either transport their content to endosomes or exocytose 
the content back to the cell surface. Some nanoparticles are able to escape the endosomes and 
access the cytoplasmic and nuclear targets (Chou et al., 2011; Kettiger et al., 2013). 
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Figure 1.7: The intracellular uptake of nanoparticles through endosomal/lysosomal pathways. (ERC) Endocytic 
recycling compartment, (ER) Endoplasmic reticulum, (MTOC) Microtubule organizing centre, (MVB) 
Multivesicular bodies (Chou et al., 2011). 
 
Nanoparticle biodistribution studies is the method for understanding the intracellular 
trafficking and fate of nanoparticles in an in vivo system (Tiwari et al., 2011). Although it is 
known that nanoparticle distribution is  influenced by the size (Cho et al., 2009; Sonavane et 
al., 2008; Zhang et al., 2011), shape, medium composition and surface chemistry of 
nanoparticles, the in vivo system reveals that circulation, distribution, degradation and 
excretion need to be taken into consideration. These complex relationships are still only 
partially understood (Morais et al., 2012).  
The most widely used route for nanoparticle administration is the intravenous route (IV). This 
route has direct access to the blood circulation allowing for rapid distribution throughout the 
body (Hirn et al., 2011). One of the first concerns of nanoparticle injection is their state of 
dispersion within solution as agglomerates may cause an embolism. When nanoparticles reach 
the systemic circulatory system, they are encounter blood constituents such as plasma proteins 
(e.g. albumin, opsonins) prior to their encounter with the plasma membrane of cells (Morais et 
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al., 2012). A protein corona forms on the surface of the nanoparticle changing the surface 
properties of the nanomaterial. 
In vivo biodistribution studies of AuNP have been increasing over the past few years focusing 
mainly on citrate-coated AuNP intravenously injected into rats (Balasubramanian et al., 2010; 
Hirn et al., 2011; Lipka et al., 2010) or mice (Cho et al., 2010; Sonavane et al., 2008). The 
findings of these studies suggest that the distribution of AuNPs, taken 24 hours after 
intravenous injection were proved to be dependent on the size of the injected nanoparticle. 
According to Jong et al (2008), the smallest particle, 10 nm had a widespread distribution with 
a higher concentration found within the liver followed by the blood, spleen, kidney and lungs.  
10, 100, 250 nm AuNps were mostly found in the liver, spleen and blood (Balasubramanian et 
al., 2010; De Jong et al., 2008). A positively charged surface has also shown to affect the 
biodistribution of AuNP resulting in their accumulation within the kidneys whilst non-charged 
or negatively charged particles showed a high accumulation within the liver (Balogh et al., 
2007). 
One of the obstacles that nanoparticles face is the reticuloendothelial system (RES). The 
reticuloendothelial system (RES) consists of fixed macrophage cells within organs such as 
liver, spleen, lymph nodes, kidney, lung and bone marrow as well as circulating macrophages 
and monocytes. The purpose of this system is to remove any foreign material in the body 
(Gupta & Kompella, 2006). Small size nanoparticles (<20 nm) have been shown to avoid the 
RES as they attract fewer opsonins resulting in longer distribution within the capillaries and 
tissues (Papasani et al., 2012). Another way to overcome this problem is through the addition 
of a polymer such as polyethylene glycol (PEG) on the surface of the AuNP. PEG is known to 
be biocompatible and non-immunogenic, reducing the cytotoxicity and prolonging the half-life 
of nanoparticles (Lipka et al., 2010).  Alternatively surface ligands such as peptides have shown 
to improve stability, biocompatibility and solubility and most importantly employ cell-
targeting. The accumulation of gold nanoparticles in tumours after systemic administration is 
also attributed to the enhanced permeability and retention effect (EPR). Angiogenesis often 
occurs at the site of tumour development. This creates a “leaky” region of vasculature, inducing 
the EPR effect. Blood vessels in the tumour could contain gaps up to 600 nm between the 
adjacent epithelial cells which allows for higher concentration of nanoparticles accumulation 
as compared to normal tissue (Arvizo et al., 2011). 
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Taking all the above into consideration, it is clear that once nanoparticles prove to have the 
potential of being used as a diagnostic or as treatment, it needs to tested in an in vivo system. 
1.11. The analysis of gold nanoparticle uptake and distribution 
 
The evaluation of the uptake and distribution of gold nanoparticles can be analysed by various 
techniques (Hillyer & Albrecht, 2001). For evaluating organ distribution, including the kinetics 
of nanoparticle accumulation and excretion; radioactive labelling analysis, instrumental 
neutron activation analysis (INAA), inductive coupled plasma-mass spectroscopy (ICP-MS) 
and atomic absorption spectroscopy (AAS) (Mohamed Anwar & Halim, 2012) are common 
techniques used. INAA and ICP-MS are commonly used for the quantification of gold in tissue 
samples (Khlebtsov & Dykman, 2011). 
Widely used techniques used to study the cellular uptake of nanoparticles are microscopy and 
flow cytometry. Flow cytometry allows for the fast quantification of nanoparticle uptake 
however does not provide an insight into the subcellular localization of nanoparticles as do 
electron microscopy. For the purpose of identifying and evaluating the localization of gold 
nanoparticles as well as their structural and elemental analysis, electron microscopy is the 
preferred and most commonly chosen technique. 
1.12. High resolution transmission electron microscopy 
 
In high resolution transmission electron microscopy (HRTEM), an electron beam is transmitted 
through an ultrathin biological sample, typically < 100 nm thick. In essence an image is formed 
from the electron interaction. This imaging technique can be used to determine the crystallinity 
and morphology of gold nanoparticles, the intracellular structure of biological material as well 
as the uptake mechanisms within cells (Lucocq & Gawden-Bone, 2010; Sperling et al., 2008). 
This can be done with a thousand times smaller resolution than light microscopy could provide 
(Goodhew et al., 2000) 
Immunogold staining for antigen localization on ultrathin sections is one of the traditional uses 
of gold nanoparticles in transmission electron microscopy (TEM). With this technique 
subcellular structures are stained with gold nanoparticles functionalized to antibodies specific 
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to the antigen exposed on the surface of the ultrathin section.  Gold nanoparticles possess a 
high electron density and can be easily  detected under TEM (Lucocq & Gawden-Bone, 2010). 
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1.13. Aims and objectives 
 
The aim of this research is to investigate the localization of three nanoparticle/peptide 
conjugates (AuNP-p.C, AuNP-p.L and AuNP-p.14) in cells and tissues of an in vitro and in 
vivo colorectal cancer model using high resolution transmission electron microscopy 
(HRTEM).  
With this general aim in mind the three main objectives considered in this investigation were 
as follows:  
1. To optimize and establish a colorectal cancer animal model using the AOM/DSS method 
2. To evaluate the specific binding and localization of peptide-gold nanoparticles 
conjugates to colorectal cancer tumours compared to non-colorectal cancer using 
HRTEM. 
3. To investigate the specific binding and localization of peptide-gold nanoparticles in 
cancer cell lines using HRTEM. 
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1.14. Thesis Scope 
 
Chapter one begins the literature review, which provides an overview of colorectal cancer 
carcinogenesis, carcinogen-induced animal models, the diagnosis of CRC, the background to 
cancer screening peptides, gold nanoparticles and their cellular uptake mechanisms. Finally, 
aims and objectives are discussed to bring the project into context and assist in the elucidation 
of the methadology to be used throughout this investigation. 
 
Chapter two provides a comprehensive description of the final methods and materials used 
during this investigation  
 
Chapter three provides the reader with visual representation of all data obtained as well as 
interpretation of the data and discussion of the results obtained. 
 
Chapter four provides the reader with the final conclusions and possible improvements to the 
project. 
 
Chapter five accounts for all references in this dissertation 
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CHAPTER TWO: METHODS AND MATERIALS 
2.1. Materials and methods 
 
All the chemicals were of reagent grade and were used without further purification. Distilled 
water was further purified using Mili-Q reagent grade system. All glass wear was cleaned using 
aqua regia. 
 
2.2. Solutions and buffers 
 
 1 M phosphate buffer (PB) - 3.1 g of NaH2PO4.H2O, 10.9 g of Na2HPO4 (anhydrous) 
in 1 L MiliQ  water (Stored up to 1 month, at 4°C, pH 7.4).  
 1 x phosphate buffer saline (PBSA) - 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g 
KH2PO4 in 1L MiliQ water (Stored up to month, at 4°C, pH 7.4) 
 Cocktail fixative (Tissue) - 2.5% glutaraldehyde and 2% paraformaldehyde in 
phosphate buffer saline (PB) at pH 7.4. 
 Cocktail fixative (Cell culture) - 2.5% glutaraldehyde and 2% paraformaldehyde in 
phosphate buffer saline (PBS) at pH 7.4. 
 DMEM complete medium: 10% FBS (5 mL), fill up with DMEM in sterile 50 ml 
tube. Complete medium was stored at 4°C 
Azoxymethane (AOM) Sigma-Aldrich 
Dextran sodium sulphate (DSS) (5 kD) Sigma-Aldrich 
Paraformaldehyde Agar scientific 
Glutaraldehyde Agar Scientific 
Molecular grade ethanol Spellbound solutions 
LR White resin Agar Scientific 
DMEM ATCC 
FBS Lonza 
EMEM Sigma-Aldrich 
NAA Lonza 
Trypsin Lonza 
DMSO Sigma Aldrich 
300-mesh carbon-copper grids  SPI Supplies 
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 EMEM complete medium: 10% FBS (5 mL), 1% NEAA (500 µL), fill up with EMEM 
in sterile 50 ml tube. Complete medium was stored at 4°C 
 Cryopreservation medium- 20% FBS, 5% DMSO to respective growth media. Make 
fresh. 
 50% (v/v) Ethanol.  Ethanol (5 mL) was made up to 10 mL with dH2O. 
 70% (v/v) Ethanol.  Ethanol (7 mL) was made up to 10 mL with dH2O. 
 90% (v/v) Ethanol.  Ethanol (9 mL) was made up to 10 mL with dH2O. 
 Resin: Ethanol (1:1).  LR White (100 µL) was mixed with an equal amount of absolute 
ethanol (100 µL). 
2.3. Gold nanoparticles and characterisation 
 
Colloidal gold nanoparticles were synthesized by Mintek (Randburg, South Africa). The 
respective AuNPs were conjugated to three peptides (p.C, p.L and p.14) through streptavidin-
binding at Minpeptide (Randburg, South Africa). Table 2 lists the peptide-gold nanoparticle 
conjugates. The size, morphology, UV-vis absorption peak were determined by the 
manufacturer. To validate the product supplied, the size and morphology were analysed using 
the HRTEM. No data regarding their size and surface charge in solution was provided; this was 
obtained using the dynamic light scattering technique (DLS) and zeta potential (ZP).  
Due to a confidential agreement, the sequences of the peptides are not mentioned here. 
Table 2: Peptide-gold nanoparticle conjugates 
 
 
 
 
 
2.3.1. High resolution transmission electron microscopy 
 
Electron micrographs were obtained using a JEOL JEM 2100 LaB6 (NMMU) microscope. The 
samples were prepared by placing 1 part of the colloidal solution (AuNPs dispersed in dH20) 
in 1 part of 99.9% absolute ethanol onto a 300-mesh carbon copper grid. In transmission 
 
Peptide name 
 
Peptide sequence 
 
p.C 
 
 
p. L 
 
 
p.14 
 
29 
 
electron microscopy (TEM), an image is formed from the interaction of high energy electrons 
transmitted through the specimen. The image presents areas of mass-thickness contrast; where 
areas of higher density and thickness appear darker in contrast whilst areas of low density and 
thickness appear lighter in contrast. This provides information on the size and morphology of 
gold nanoparticles (AuNP) and biological structures (Miller & Lines, 1988; Wang, 2000).  
2.3.2. Energy dispersive X-ray spectroscopy 
 
Samples were analysed in the HRTEM equipped with energy dispersive X-ray spectroscopy 
(EDS, X-Max 80, Oxford Instruments) detector. This technique provided elemental and 
chemical analysis of nanomaterial being probed (Wu et al., 2013). The interaction of electron 
beam on the sample produces X-rays that are characteristic to the elements present within the 
sample. The HRTEM samples (see section 2.3.2) have been analysed by EDS.  
 2.3.3. Dynamic light scattering and zeta potential 
 
Dynamic light scattering (DLS) and zeta potential (ZP) measurements were performed on 
Zetasizer Nano using a Size and Zeta folded cell: DTS1060 at room temperature (RT) (Malvern 
Instruments). DLS characterizes the hydrodynamic radii (HD) of particles in solution (i.e. the 
inorganic core, as well as the surface modification). It is based on the measurement of light 
being scattered as a laser passes through a colloidal solution undergoing Brownian motion (at 
a constant temperature). By analysing the scattered light intensity as a function of time, this 
generates diffusion coefficients which are mathematically linked to the particle size and size 
distribution. ZP technique measures the movement of the charged particles in an electric field. 
This value is a useful in determining the stability of the suspension (i.e. large negative or 
positive zeta potential indicates better stability) and understanding nanoparticle-cell 
interactions (Wang et al., 2009). Each sample was measured in triplicate and the mean value 
reported. 
2.4. In Vitro Studies 
2.4.1. Routine cell culture maintenance  
 
Human epithelial colorectal adenocarcinoma (Caco-2, HT-29) and hepatocellular carcinoma 
(C3A) cell lines were cultured in 10 cm culture dishes. The Caco-2 and HT-29 cell lines were 
30 
 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with glutamine 
and 10% (v/v) fetal bovine serum (FBS). The C3A liver cell line was maintained in Eagles 
Minimum Essential Medium (EMEM) supplemented with 1% non-essential amino acids 
(NAA) and 10% (v/v) FBS. All solutions were stored at 4°C and pre-warmed to 37°C in a 
water-bath prior to use. The cells were maintained in 5% C02 at 37°C (Celis et al., 2005). 
Cells were subcultured after 70-80% confluency. Subculturing was performed by removing 
media from the attached cells. Cells were washed with 10 mL phosphate buffered saline 
(PBSA) and trypsinized by adding 1 mL of 0.25% trypsin (v/v). Cell detachment was facilitated 
by placing the dish in the 37°C incubator for 5-10 minutes. The cells were re-suspended in 2 
mL of media, after which the cells were plated (1:3 ratio) into new culture (Ng et al., 2010; 
Schrand et al., 2010). 
2.4.3. Storing and thawing of cell culture 
 
Confluent cells (70-80%) were detached from the cell culture dishes as described above in 
section 2 and centrifuged for 5 minutes at 500g. The pellet generated was re-suspended in 3 
mL fresh complete media. Cells were microscopically counted using a haemocytometer and 
trypan blue. 1x106 cells/ml were re-suspended in cryopreservation media. The cryo-tubes were 
placed at -80°C (Celis et al., 2005). 
2.4.4. Cell culture nanoparticle exposure 
 
HT-29, Caco-2 and C3A cell lines were seeded in 10 cm culture dishes at a cell density of 3x 
105/ml and grown to a desired confluence. The cells were treated with AuNP-p.C, AuNP-p.L 
and AuNP-p.14  (1 nM)  for 6 hours, at 37°C as established by the cellular uptake kinetics of 
14 nm AuNPs in Hella cells previously evaluated by Chithrani et al. (2006). 
2.4.5. TEM cell preparation 
 
The preparation of biological samples (i.e. cells and tissue) for electron microscopy requires 
several stages which includes sample washing, fixation, dehydration, embedding, sectioning 
and analysis as seen in Figure 2.1. The cell preparation for electron microscopy was performed 
as described by Schrand et al. (2010), with minimal modification. 
31 
 
 
 
 
 
 
 
                                       A. Grow cells and treat cells with AuNPs 
                                                
 
 
 
 
 
                              B. Rinse, pellet, dehydrate and embed cells in LR White resin 
                                                  
 
 
 
 
C. Polymerization in                D. Trim and section samples   E.  Image in JEOL JEM 2100                                                                                                         
     oven at 60°C                             ultramicrotome (NMMU)        LaB6                                                                                           
Figure 2.1: Overview of sample preparation process (A-E). (A) Grow and dose cells with AuNPs, (B) Cell 
processing (rinse, pellet, dehydrate, embedding), (C) Curing, (D) Trim and sectioning of sample, and (E) 
Imaging with HRTEM. 
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2.4.5.1. Sample washing and harvesting 
 
Before sample harvesting, the cell monolayer should be washed thoroughly. This is important 
as the surface may contain a variety of unwanted deposits such as media components, 
free/unattached gold nanoparticles, cellular debris or contaminants. If these deposits are not 
removed prior to centrifugation and fixation procedure, the material may get permanently fixed 
to the specimen surface. The cells monolayer as described in section 2.4.4, was washed three 
times with PBSA (pH 7.4) at room temperature (RT). 1 mL of PBSA was added to each cell 
dish and scraped off the plate. The cell suspension was transferred to eppendorfs and 
centrifuged at 1000g to generate a cell pellet (Ng et al., 2010; Schrand et al., 2010). 
2.4.5.2. Fixation 
 
The first critical stage of biological preparation for electron microscopy is fixation. The aim of 
fixation is to preserve the structure of the cell (shape, size, 3D dimensional organisation, 
cellular activity) and protecting the cell from structural deformation that could occur during 
dehydration, embedding, sectioning and staining (Newman et al., 1982, 1983). After cell 
harvesting, the PBSA was removed from the eppendorf tubes and replaced with a fixative 
cocktail of 2.5% glutaraldehyde and 2% paraformaldehyde in PBSA at pH 7.4. This was left 
to incubate for 2 hours at RT (Schrand et al., 2010). 
2.4.5.3. Dehydration 
 
The aim of the dehydration process is to remove water from the biological sample by the 
addition of increasing concentrations of an organic solvent such as ethanol (Hayat, 1974; 
Newman & Hobot, 1999). This is essential as the biological sample may be embedded in a 
water-insoluble resin such as LR White. After the fixation process, samples were washed thrice 
with PBSA (pH 7.4) for 10 min. This was carried out in order to minimize the possible reaction 
of fixative and dehydration reagent. The dehydration procedure was carried out with a series 
of 50, 70, 90 and 100% (2x) molecular grade ethanol concentrations for 15 min each (Hayat, 
1974). 
2.4.5.4. Embedding in LR White resin 
 
LR White is a polyhydroxy aromatic acrylic resin introduced by Causton (1984). After the 
dehydration procedure, the cell pellets were gradually infiltrated with LR White resin and 
100% ethanol at a ratio of 1:1 for 1 hour (Hayat, 1974). The cell pellets were transferred to a 
33 
 
BEEM gelatin capsule. The gelatin capsules were filled with pure LR White resin to generate 
a positive meniscus and covered to exclude oxygen. Geletin capsules were incubated for 4 
hours at 4°C. This allowed for complete infiltration before polymerization at 60°C for 38 hours. 
Post-fixation/staining with heavy metals were avoided to prevent possible interference (i.e. 
heavy metal artefacts) with the identification of gold nanoparticles (Hillyer & Albrecht, 2001; 
Jong et al., 2010). 
2.5. In vivo Studies 
2.5.1. Ethical approval 
 
This study was approved by the Animal Research Ethics Committee (REC-A) of Nelson 
Mandela Metropolitan University (A13-SCI-ZOO-013). 
 
2.5.2. Animal maintenance 
 
Healthy adult male Wistar laboratory rats (15 weeks of age) were obtained from North West 
University animal institute (South Africa). Animals were housed five per cage. The Animals 
were maintained at a temperature of 22°C (± 3°C), with a 12 hour light and 12 hour dark cycle. 
All animals were fed standard commercial rat chow and given distilled water ad libitum.  
 
2.5.3. Animals and experimental design 
 
After weaning, 35 male Wistar rats were assigned to six groups, five experimental groups and 
one control group.  
 Experimental group (group 1, group 2 and group 3; n=6) were assigned to the colorectal 
cancer induction experiment and treated with AuNP-p.C, AuNP-p.L and AuNP-p.14. 
Experimental group 1 was subjected to the AOM/DSS method 1. Experimental group 
2 and 3 were subjected to AOM/DSS method 2. 
 Experimental group (Group 4 and 5; n=6) were maintained as healthy rats treated with 
AuNP-p.C and AuNP-p.14. This was performed as a means to evaluate and gain a firm 
understanding of AuNP biodistribution/accumulation between tumour-bearing and 
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non-tumour bearing (healthy) rats. An additional healthy group treated with AuNP-p.L 
was not carried out due to animal breeding constraints and timing. 
 Control group (group 6; n=5) were healthy and did not receive any treatment. Table 2 
lists the Animal experimental procedure and design  
 
After rats were sacrificed (see section 2.6.5) and tissue was collected (see section 2.6.7), all 
tissue pieces from animal groups were processed for HRTEM (section 2.6.8). Due to time 
constrains, tissue from AOM/DSS method 1 (colon, rectum, pancreatic and kidney), Group 4 
(kidney) and Group 5 (liver) were analysed. See Figure 2.2, a schematic diagram of research 
design. 
 
 
Figure 2.2: Schematic diagram of research design and electron microscopy evaluation 
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2.5.4. Induction of colorectal cancer 
 
2.5.4.1. AOM/DSS method 1 
 
Wistar rats were assigned to three CRC induction-experimental groups. Group 1 was subjected 
to the AOM/DSS method 1, and later treated with AuNP-p.L. This was done in conjunction 
with a control group (group 6). The control group represents a healthy non-treated AuNP study.  
The standard AOM/DSS method 1 procedure was followed as described by Thaker et al. 
(2012). Male Wistar rats (n=6) were given a single intraperitoneal injection of AOM (12 mg/Kg 
body weight) at week 1 followed by 1 week of distilled water. At week 3, 3 cycles of DSS (1 
cycle included 2% DSS with a molecular weight of 5kDa for 1 week followed by distilled water 
for 2 weeks) were administrated. At the end of week 11, the animals were monitored for an 
additional 2 weeks before all animals (group 1) were intravenously injected with AuNP-p.L 
(week 14) and sacrificed 24 hours later. Each week the body weights of the animals were 
recorded. Figure 2.3 illustrates the AOM/DSS method 1 procedure. 
 
 
Figure 2.3: AOM/DSS method 1: The establishment of a CRC rat model. W1-14:Weeks 1-14, AOM–
Azoxymethane injections (grey box), DSS- 2% dextran sodium sulphate administration (black box), dH20- normal 
distilled water (White box), AuNP- AuNP injection (red box). 
 
2.5.4.2. AOM/DSS method 2 
 
The decision was made to alter the AOM/DSS protocol by Thaker et al. (2012) to assist in 
obtaining colorectal cancer tumours. Wistar rats assigned to CRC induction-experimental 
groups (group 2 and 3) followed the AOM/DSS method 2 procedure.  
Wistar rats (n=6) were given a single intraperitoneal injection of AOM (12 mg/Kg body 
weight) at week 1 followed by 1 week of distilled water. At week 3, 2 cycles of DSS (1 cycle 
included 2% DSS with a molecular weight 5kDa for 1 week followed by distilled water for 2 
weeks) were administrated. After the 2 cycles of DSS treatment, both groups were given a 
second AOM injection (12 mg/kg body weight) at week 9. This was followed by the 
administration of a 2 cycles of DSS at week 12 and 15. At the end of week 17, the animals 
14 Week AOM dH20 DSS dH20 DSS dH20 DSS dH20 dH20 AuNP 
Group 1 
n=6 
W1 W2 W3 W4+5 W6 W7+8 W9 W10+11 W12+13 W14 
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were monitored for an additional 2 weeks before all animals (group 2 and group 3) were 
intravenously injected with AuNP-p.C (group 2) and AuNP-p.14 (group 3) and sacrificed 24 
hours later. Each week the body weights of the animals were recorded. Figure 2.4 illustrates 
the AOM/DSS method 2 procedure. 
 
 
Figure 2.4: AOM/DSS method 2: The establishment of a CRC rat model. W1-14:Weeks 1-14, AOM-–
Azoxymethane injections (grey box), DSS- 2% dextran sodium sulphate administration (black box), dH20- 
distilled water (White box), AuNP- AuNP injection (red box). 
 
Due to time constraints of this study and the high cost in the development and maintenance of 
inducing colorectal cancer, the AOM/DSS method 2 was initiated after the third and last DSS 
cycle of the AOM/DSS method 1. The rats were then injected with AuNP/peptide conjugates 
after the AOM/DSS treatment for evaluating the nanoparticle targeting efficiency. This was 
done in conjunction with a control group (group 6). 
 Currently there are no sensitive and specific techniques available other than colonoscopy to 
detect early stage colorectal cancer. Colonoscopy would be difficult in this research setup, thus 
rats were treated with gold nanoparticles and sacrificed at the time expected to develop 
colorectal cancer. According to the literature, the percentage of weight loss is a sign of 
colorectal cancer development and was used in this study. Other signs such as rectal bleeding 
and diarrhoea are indicative of a late stage in the development of colorectal cancer and was 
therefore not applicable in this study. 
2.5.5. Sacrifice of rats 
 
Prior to necroscopy, final weight measurements were taken before individual rats were given 
an intramuscular injection of Ketamine (100 mg/kg body weight) as an anaesthetic. After no 
signs of sensory reflexes, blood was withdrawn via cardiac puncture which caused 
hypovolumic death. All rats were laid on their ventral side exposed on a cutting board. The 
abdomen was covered with 70% ethanol to prevent hairs from contaminating abdomen content. 
Forceps were used to grasp the midline of the abdomen. A small incision was then made to 
20 
Week 
AOM dH20 DSS dH20 DSS dH20 AOM dH20 DSS dH20 DSS dH20 dH20 AuNP 
Group 
2 + 3 
n=6 
W1 W2 W3 W4+5 W6 W7+8 W9 W10+11 W12 W13+14 W15 W16+17 W18+19 W20 
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expose the peritoneum. This incision was extended to both sides of the abdomen along the 
costal margin. Scissors were used to cut through pelvis for exposing the rectum (Thaker et al., 
2012). Figure 2.5., shows the necroscopy process 
 
 
 
 
 
 
 
 
    
    A 
 
 
 
 
 
 
 
 
       B 
 
 
 
 
 
 
 
 
      
      C 
 
 
 
 
 
 
 
  
     D 
Figure 2. 5: Rat necroscopy: (A) The tendon reflex is used to assess the level of consciousness of the rat, (B) 
Blood is removed from heart before necroscopy procedure, (C) The abdomen is cut exposing the abdominal 
viscera, and (D) The removal of the large intestine.  
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2.5.6. Tissue harvesting 
 
After sacrificing the animals, the colon, small intestine, spleen, kidney, liver, brain, heart and 
lungs were rapidly removed to prevent autolysis. Due to time constraints of this research 
project, emphasis was placed on the colon in particular. The colon was removed, cut open 
longitudinally along the main axis and washed with saline. All tissue were cut into 1 mm3 
pieces. 
2.5.7. TEM tissue preparation 
 
Tissue pieces (1 mm3) removed from the sacrificed animals was prepared for TEM as 
established in section 2.4. The tissue pieces were fixed in a mixture of 2.5% glutaraldehyde 
and 2% paraformaldehyde in 0.075 M phosphate buffer (PB) pH 7.4, at room temperature (RT) 
overnight. After three washes with phosphate buffer, the tissue pieces were dehydrated at room 
temperature through a series of ethanol concentrations at 50, 70, 90 and 100% (2x). After 
dehydration, tissue pieces were gradually infiltrated with LR White resin and 100% molecular 
grade ethanol at a ratio of 1:1 for 1 hour at room temperature. The samples were then embedded 
in pure LR White resin for 4 hours before polymerization at 60°C for 38 hours (Ng et al., 2010; 
Skepper & Powell, 2008). Post-fixation/staining with heavy metals were avoided to prevent 
possible interference (i.e. heavy metal artefacts) with the identification of gold nanoparticles 
(Hillyer & Albrecht, 2001; Jong et al., 2010). 
 
2.5.8. Ultramicrotome methodology for sectioning ultrathin sections. 
 
The aim of tissue processing is to embed the tissue in a solid medium firm enough to support 
the cells/tissue and give it sufficient rigidity to enable thin sectioning. The cell and tissue 
samples chosen were sectioned using the LKB standard glass knifemaker (Ng et al., 2010; 
Skepper & Powell, 2008). Before the sections were cut, glass knives were prepared, as seen in 
Table 3. 
Ultrathin sections (80-100 nm) were cut with using the Reichart UltracutE ultramicrotome. 
Sections were transferred to 300 – mesh carbon copper grid. 
 
39 
 
 
 
 
 
Table 3: Glass knife preparation for ultrathin sectioning (Adapted from Wickens (2012)) 
 
MAKING GLASS KNIVES 
STEP ACTION 
1.   
A 25mm wide x 200mm long x 6mm thick glass strip was washed with soapy water and/or alcohol to 
remove grease and dirt. This was allowed to dry on a paper towel. 
2.   
The scoring bar was pushed in and the score selector was set to parallel lines. 
3.   
The breaking knob was pushed counter clockwise. 
4.   
The glass strip was placed on the LKB machine, resting against a white plate and pressing against a 
black stud. 
5.   
Whilst the glass was held in place, the clamping head was lowered until it touched the glass strip. The 
clamp was then securely tightened. 
6.   
The scoring shaft was then pulled to create a scoring line in the glass. 
7.  
 
 
The breaking knob was then turned clockwise until the glass broke. 
8.   
The glass knob was immediately returned to fully counter-clockwise position and clamping head lifted. 
9.   
The glass square was then placed turned counter clock wise from its original cutting position using the 
fork. The glass was then placed between two glass holders (“corners”). 
10.   
A securing knob was used to clamp the square glass between tow forked holders. 
11.   
The damping pad was lowered until it touched the glass. 
12.   
The scoring bar was then turned to 25 mm thickness and glass square scored by pulling the scoring shaft 
outwards. 
13.   
The breaking knob was then turned clockwise slowly until the square broke. 
14.   
The clamping head was immediately lifted, scoring shaft returned and breaking knob turned clockwise. 
15.   
The glass knife was then released carefully the fork. 
Sectioning at 80- 100 nm 
1.   
A glass boat was made with silver tape and secured with dental wax/ nail paint 
2. 
 
  
The glass knife was placed securely in the knife holder 
2.  The boat was filled  with clean filtered  water to a level below the knife edge 
3.   
The knife holder was fitted into the cutting arm and fastened tightly. 
4.   
Once the alignment was set, the macro-feed wheel was brought forward to almost touch the knife 
5.   
The rough sample block was lightly trimmed 1 um at a time. 
6.   
Once the sample block face was smooth, the auto wheel was turned on and the ultramicrotome cut 70-
100 nm sections into the water bath (Silver- Gold ultrathin sections) 
7.   
When a suitable ribbon was cut, the sections were stretched with chloroform fumes. 
8.   
The sections were then lifted onto TEM grids using forceps and allowed to dry for 30 minutes 
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2.5.9. Statistical analysis 
Results were statistically analysed using Student’s t-test in conjunction with GraphPad Prism 
6.0. P value <0.05 was considered significantly different 
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CHAPTER THREE: RESULTS AND DISCUSSION 
 
Results and discussion consists of three sections; characterization of AuNPs (section 3.1), In 
vitro studies (section 3.2) and In vivo studies (section 3.3). 
3.1. Characterization of AuNPs 
3.1.1. Aims of investigation 
 
The characterisation of nanoparticles (i.e. size, shape and surface functionalization) are critical 
issues for the delivery of nanoparticles as well as understanding their cellular interactions 
(Jiang et al., 2009). The peptide-AuNP conjugates were obtained from Mintek. The size and 
morphology of the AuNPs were characterised by researchers at Mintek. For control and 
observation purposes, this was confirmed using HRTEM (as described in section 2.3). 
3.1.2. Results 
 
3.1.2.1. Characterisation by high resolution transmission electron microscopy 
 
Table 3 summarises the measurements of the three peptide-AuNP conjugates. The majority of 
AuNPs were spherically shaped with an average size of 14 nm. A general view over the TEM 
grids confirmed the presence of stable particles. As depicted in Figure 3.1 (A, B and C), the 
core of the AuNPs possess a dark contrast with resolved lattice fringes (indicated by lattice 
fridges). It was observed that AuNP-p.C (Figure 3.1.A) and AuNP-p.14 (Figure 3.1.C) were 
surrounded by a transparent layer indicated by a black arrow. No such layer was observed for 
AuNP-p.14 (Figure 3.1.B).  
 
3.1.2.2. Characterisation by dynamic light scattering and zeta potential 
 
As depicted in Table 4, the HD of AuNPs-p.C and AuNPs-p.L and AuNPs-p.14 were found to 
be approximately 11 nm larger than the core diameters measured by HRTEM (as described in 
section 3.1.2.2). The data further reports low polydispersity index, high zeta potentials and a 
negative surface charge.  
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Figure 3. 1: TEM Bright field (BF) images of (A) AuNPs-p.C, (B) AuNPs-p.L and (C) AuNPs-p.14. Black 
arrow indicates layer around AuNP. White arrow indicates lattice frindges. 
 
Table 4: The characterisation of gold nanoparticles attached to peptide  
 
AuNP-peptide DLS 
(nm ± std 
dev) 
TEM 
(nm ± std dev) 
(as supplied) 
Zeta-
Potential 
(m.V) 
Suspension 
media 
(as supplied) 
UV-vis 
Absorption 
peak 
Polydispersity 
AuNP-p.C 25.30 ± 0.115 14±3 nm -22.40 MiliQ water 521 nm 0.196 
AuNP-p. L 24.63 ± 0.77 14±3 nm -42.3 MiliQ water 523 nm 0.399 
AuNP-p.14 24.40± 0.055 14±3 nm -67.6 MiliQ water 524 nm 0.148 
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3.1.3. Discussion 
 
Gold nanoparticles have attracted considerable attention in biological applications. The unique 
properties exhibited by gold nanoparticles are attributed to their physicochemical 
characteristics. Determining these characteristics could play a vital role in understanding  how 
gold nanoparticles associate with the living system (Jiang et al., 2009). 
HRTEM micrographs confirmed spherical shaped AuNPs showing lattice fringes indicative of 
good structural quality gold nanoparticle conjugates (Wang, 2000). Due to mass-thickness 
contrast AuNPs are of darker contrast, however, biomolecules are of low density and therefore 
appear “electron transparent” (i.e. unless stained with heavy metals) (Chatterjee et al., 2012). 
In this study, it seems that the lattice fridges of AuNPs seen in Figure 3.1 (A and C) cannot be 
clearly seen. It is suggested that this could be due to the layer/coating surrounding the AuNP-
p.C and AuNP-p.14. This layer is presumed to be the peptide molecules conjugated to the 
AuNPs. The lattice fridges of AuNP-p.L are the most visible as seen in Figure 3.1.B, which 
could be a result of no layer/coating being observed around the nanoparticle structure. The 
absence of the layer/coating surrounding AuNP-p.L (Figure 3.1.B) could be due to sample 
preparation of peptide-AuNP conjugates for TEM (as demonstrated in section 2.3) or the 
application of the TEM beam. This is just a suggestion; such an observation is best studied 
using DLS, which has confirmed a size difference of approximately 11 nm for all three AuNPs 
due to peptide conjugation. DLS and zeta potential measurements further report that the AuNP 
solution is well dispersed, free from aggregation or agglomeration (Yin Win & Feng, 2005). 
3.2. In vitro studies  
3.2.1. Aim of investigation 
 
Mazyambe (2013) demonstrated that binding of quantum dot nanoparticles conjugated with 
p.C was highly specific towards Caco-2 and HT-29 cells, while quantum dot nanoparticles 
conjugated with the p.L peptide demonstrated specificity towards HT-29 cells. The objective 
of this section was to further investigate the uptake and localization of nanoparticles (gold 
nanoparticles) conjugated with these peptides. A third peptide (p.14), which was demonstrated 
to have selectivity towards colon cancer cells (Wang et al., 2012), and which was not part of 
the Mazyambe study was also included in the current study. While  Mazyambe’s study used 
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flow cytometry to study the binding of the fluorescent nanoparticles to the cells, the current 
study used HRTEM to study the uptake and localization of the AuNP/peptide conjugates 
(AuNP-p.14, AuNP-p.C and AuNP-p.14) in colorectal cancer cells (Caco-2 and H-T29) and 
liver cancer cells (C3A). The cells were exposed to the AuNP/peptide conjugates and the 
uptake and localization of the nanoparticles were then studied using HRTEM as described in 
section 2.4.5. 
 
3.2.2. Results  
 
Electron micrographs of HT-29 cells treated with AuNP-p.14 (Figure 3.2.A, B) and AuNP-
p.C (Figure 3.3.A, B) displayed features which included increased cell volume, intact 
nucleus, distortion of all subcellular organelles, a disruption of the plasma membrane and the 
release of cellular components into extracellular space. 
 
A                                                                                       B 
Figure 3. 2: TEM (BF) micrographs of HT29 cell line treated with AuNPs-p.14 (n=1). (A, B) Two arrows 
indicate the cell membrane; single arrow indicates the cell nucleus.  
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A                                                                                    B 
 
 
Figure 3. 3: TEM (BF) micrographs of HT29 cell line treated with AuNPs-p.C (n=1). (A, B) Two arrows 
indicate the cell membrane and single arrow indicates the cell nucleus. 
 
3.2.3. Discussion 
 
It is empirical to the aims of this study to be able to identify AuNPs but also permit the 
visualization of cellular components and organelles. This can only be seen if the cells were 
suitably prepared for electron microscopy. If prepared appropriately, the expectation is that the 
appearance of cells should approximate that of living cells. This assumption finds support from 
the mass-basis TEM procedure adapted from Schrand et al. (2010). 
 
However, in this study the fine cellular structure of the cells could not be preserved. HT-29 
cells  as depicted in Figure 3.2 (A,B) and Figure 3.3(A,B) displayed features which included 
increased cell volume, intact nucleus, distortion of all subcellular organelles, a disruption of 
the plasma membrane and the release of cellular components into extracellular space. These 
features were all indicative of necrotic cell death. Necrotic cell death occurs when cells are 
exposed to extreme variance in physiological conditions (Fernandez-Prada et al., 1998; Majno 
& Joris, 1995; Proskuryakov et al., 2003). In an attempt to improve the quality of sample 
preservation, several parameters from the methodology (as described in section 2.4.5) were 
identified for optimization. Table 5 lists the parameters for optimal cell preservation. No 
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selective targeting and localization of AuNPs to HT-29 cells were observed, however, these 
findings cannot be confirmed as of yet. 
 
 
Table 5: Parameters for optimal cell preservation. 
1. Cell harvesting 
a. Cell scraping/cell trypsinization 
b. Centrifugation speed 
2. Fixation of cells 
a. Fixative type 
b. Concentration 
c.    In situ fixation 
d. pH  
e. Osmolarity 
3. Dehydration of cells 
a. Time 
b. Temperature 
4. Embedding of cells 
 
 
3.2.3.1. Cell harvesting 
 
The cells were harvested from the plastic surface of the cell culture dish before fixation as 
described by Schrand et al. (2010). In this study, the cell scraping technique was chosen. This 
technique can potentially cause more damage to cell integrity compared to trypsinization 
(Magee et al., 1958). On the other hand trypsinization can possibly interfere with membrane 
associated proteins and therefore also the AuNP/peptide conjugates if the nanoparticles are 
localised to the to the membrane. Due to uncertainty of AuNP localization (intracellular or 
membrane association), trypsinization was abandoned and the cell scraping technique was 
used. It is also possible that the cells optimal growth conditions were compromised before cell 
fixation. We therefore propose to investigate an alternative technique known as in situ fixation.  
In this way, the cell monolayer in culture dish goes undisturbed whilst being preserved (Ryan 
& Hart, 1986). 
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Another contribution to cell damage prior to the fixation step could be the high centrifugal 
forces during centrifugation (in this study 1000g for 5 minutes was used). There is no well-
defined speed to centrifuge cells into a pellet for TEM processing.  Schrand et al. (2010) have 
utilized 1000g in their studies, whilst Nativo et al. (2008) used 5000g and have reported good 
results. To confirm whether centrifugation plays a significant role in cell damage, HT-29 cells 
were grown under optimal conditions, detached from the cell culture dish and centrifuged at 
two centrifugation speeds (500g and 1000g). The cells were then re-suspended and cell 
viability was assessed by trypan blue staining. No significant cell damage occurred at these 
speeds. A less compressed cell pellet was generated at 500g, which could potentially cause 
difficulty with washing, dehydrating and embedding. There is also a concern that centrifugation 
forces could contribute to unwanted interactions between the nanoparticles and cells (Schrand 
et al., 2010). A lower centrifugal force with pre-shaped BEEM capsule tips would circumvent 
this confrontation and ease specimen collection and orientation in future research. 
 
3.2.3.2. Fixation of cells 
  
The electron micrographs for in vitro studies demonstrate unsuccessful preservation of HT-29 
cells. All indications of fixative artefacts. The pH, osmolarity, temperature, length of fixation 
and concentration of fixatives are critical factors in determining the quality of fixation (Hayat, 
1974; Newman & Hobot, 1999). It is therefore essential that the method of fixation needs to be 
in line with the objectives of the study (Hayat, 1974; Newman & Hobot, 1999). For the best 
results; a combination of paraformaldehyde and glutaraldehyde (Karnovsky’s fixative) is 
generally used. This has proved to be successful in preserving both ultrastructure and 
immunogenicity in cells or tissue (Griffiths, 1993; Newman et al., 1982). Paraformaldehyde is 
able to penetrate cells/tissue very quickly, reacting with uncharged primary amine groups and 
aromatic amino acid residues. It is able to stabilize the protein structure but gives poor 
preservation of ultrastructure. Glutaraldehyde penetrates tissue more slowly and reacts with 
amino acids, aromatic, carboxyl, amidozole and sulfhydryl groups. It has the ability to preserve 
ultrastructure better than any known fixative. Glutaraldehyde also increases the permeability 
of the tissues to the embedding medium (Hayat, 1974). For immunocytochemical experiments, 
cells/tissues are often fixed in paraformaldehyde (2-4%) and glutaraldehyde (0.1-0.2%) in a 
PBSA solution. However, small amounts of glutaraldehyde in the fixative would not achieve 
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adequate ultrastructural detail (Takizawa et al., 2003). To achieve ultrastructural detail, 
Schrand et al. (2010) used a 2.5% glutaraldehyde/formaldehyde fixative. In this study, a 
combination of 2.5% glutaraldehyde and 2% paraformaldehyde in PBSA solution was used to 
preserve the cultured cell samples. Immunogenicity may therefore have been compromised in 
this study as a higher glutaraldehyde percentage was used (Mühlfeld et al., 2007). The pH 
levels in the different structural compartments of the cell vary significantly (Hayat, 1974). To 
achieve the best structural for preservation, cells and tissues must be kept at a pH between 7.2 
and 7.4, with a physiological osmolarity of ~280 mOsm (Loqman et al., 2010). Throughout 
this experiment, the pH of the phosphate buffer saline was kept at 7.4. However, the osmolarity 
of the fixative was disregarded and should be looked into as it has shown to play a direct 
influence on the appearance of the cell structure  
 
Post-fixation with heavy-metals (e.g. osmium tetroxide) is usually required as it further 
stabilizes the fine structure already maintained by aldehydes but also acts as an electron stain, 
imparting a high contrast to biological material (Hayat, 1974; Sabatini et al., 1964; Schrand et 
al., 2010). In this study, the post-fixation step was omitted to prevent the electron stain and to 
elucidate the identification of gold nanoparticles present in biological material. If contrast is 
required it could be corrected for through image processing techniques, thickness during 
sectioning and staining with heavy metals (lead citrate, uranyl acetate, etc.) as demonstrated by 
Schrand et al. (2010). It is certainly possible that omission of the post-fixation step with heavy 
metals could play a part in the preservation of the cells. This needs to be investigated further. 
 
3.2.3.3. Dehydration and embedding of cells 
 
Acetone is known to interfere with LR White resin polymerization (Hayat, 1974; Schrand et 
al., 2010; Skepper & Powell, 2008). It is for this reason that ethanol was chosen as the organic 
solvent for the dehydration of the cell pellet. In this study, dehydration was gradually carried 
out with a 50, 70, 90 and 100% (2x) ethanol for 10 minutes each. This procedure is essential 
as LR White resin is water-insoluble. However, ethanol is a lipid solvent and dehydration must 
be accomplished as rapidly as possible to avoid leaching of lipids from cellular components. 
According Philimonenko et al. (2002), 5-15 minutes of dehydration each is sufficient. 
Embedding the cell sample provides additional support. It allows sufficient handling of the 
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sample when sectioning. LR White resin was chosen for its low viscosity, low toxicity and low 
extraction rate compared to alternative resins (Newman & Hobot, 1999).  
 
 
3.2.3.4. Sectioning 
 
To gain the resolution required to view individual nanoparticles and ultrastructural detail, a 
section thickness less than 100 nm is often required (Schrand et al., 2010). Section thickness 
lower than between 80 nm could not be obtained with the ultramicrotome equipment used in 
this study, and as a result the sections were of poor quality. Problems with variations in section 
thickness and vibrations also added to the poor quality of the sections. It was thought that a 
way to reduce the thickness of the sample would be to mount the section on a naked grid. This 
idea failed as stability of the section under the electron beam was reduced.  
 
Taking all the above into consideration, TEM sample preparation requires several stages, which 
include sample washing, fixation, dehydration, embedding. Each stage in sample preparation 
has a great impact in the quality of the resulting cell sample. 
3.3. In vivo studies 
3.3.1. Aim of investigation 
 
AOM/DSS is a recognised method to induce colorectal cancer.  AOM is a carcinogen that 
induces tumours in the colon whilst DSS causes inflammation.  The severity of inflammation 
hastens the development of colorectal tumours. This can be monitored by weight loss and 
pathological features such as rectal bleeding and diarrhoea (Perše & Cerar, 2005). 
The aim of this investigation was to establish and optimize a colorectal cancer animal model 
using the AOM/DSS procedure. This animal model was used to investigate the localization of 
AuNP/peptide conjugates (AuNPs-p.C, AuNPs-p.L and AuNPs-p.14) to colorectal tumours 
using HRTEM. 
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3.3.2. Results  
3.3.2.1. The induction of colorectal cancer in rat model 
 
AOM/DSS method 1:  
Group 6 (Control) showed a higher average body weight than Group 1 (AOM/DSS method 1), 
however the difference was not significant until the day of AuNP treatment (P=0.0176). This 
is illustrated in Figure 3.4. 
 
 
 
 
 
 
 
 
Figure 3.  4: Average body weight (kg) at different time points between group 6 (Control, n=5) and group 1 
(AOM/DSS method 1, n=6).  AOM denotes the body weight taken on the day of AOM injection, C1, C2 and C3 
denotes the weight taken at the end of cycle 1, 2 and 3. NP denotes the weight taken before AuNP injection.  
 
Wistar rats given the AOM/DSS method 1 treatment (Group 1) were sacrificed 24 hours after 
AuNP-p.L injection. Pathological features which include a bloody stool and diarrhoea were not 
observed.  No animals died prematurely. After each rat sacrifice, the colon was inspected for 
the presence of neoplastic lesions. This was done with the assistance of Dr. Ernest. Fredericks, 
a Gastroenterologist in private practice in Port Elizabeth (Greenacres Hospital). Majority of 
suspected lesions were excised from the distal colon for tissue processing as described in 
section 2.6.7. From the same site of excision, a second excision was made and the suspected 
lesions were removed and placed in 10% formalin. Samples were sent to Ampath, Greenacres 
Laboratory (South Africa) for analysis. Histopathological findings indicated suspected lesions 
were highly inflamed but no colorectal cancer present. See Figure 3.5.B for excision sites of 
inflamed colon tissue. 
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Figure 3.  5: Examination of colon. (A) Image of colon showing no lesions, (B) Excision sites of rat colon 
lesions indicated by black arrows. 
 
AOM/DSS method 2: 
 No significant difference in body weight between group 6 (control) and group 2 and 3 
(AOM/DSS method 2) were observed as seen in Figure 3.6.  
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Figure 3.  6: Average body weight (kg) at different time points between group 6 (control, n=5), group 2 and 
group 3 (AOM/DSS method 2, n=6). AOM-1, AOM-2 denotes the body weight taken on the day of AOM 
injection, C1, C2 and C3 denotes the weight taken at the end of cycle 1, 2 and 3. NP- denotes the weight taken 
before AuNP injection. 
 
Wistar rats in group 2 and 3 were subjected the AOM/DSS method 2. Pathological features 
such as a bloody stool and diarrhoea were not observed. The animals were sacrificed 24 hours 
after their AuNP-p.C (group 2) and AuNP-p.14 (group 3) injection. No animals died 
prematurely. The colon was inspected for the presence of neoplastic lesions. No lesions could 
be identified in AOM/DSS method 2 (as seen in Figure 3.5. A) 
Taking all the above into consideration, animals in AOM/DSS method 1 (Group 1) experienced 
significant weight loss on the last week before AuNP treatment, however did not present any 
pathological features (except for inflammation) and neoplastic lesions. Animals given the 
AOM/DSS method 2 (Group 2 and group 3) experienced no weight loss or pathological 
features and did not present neoplastic lesions. 
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3.3.2.2. HRTEM analysis of tissue 
 
This study describes the evaluation of tissue samples from inflamed colon (Figure 3.7), rectum 
tissue (Figure 3.8), pancreatic tissue (Figure 3.8) and kidney tissue (Figure 3.9) after being 
subjected to AOM/DSS method 1 treatment. Healthy liver tissue (group 5) (Figure 3.10) and 
healthy kidney tissue (group 4) (Figure 3.12) were also evaluated after being subjected to 
AuNP/peptide treatment. The tissue samples were taken 24 hours after the nanoparticles were 
injected into the animals. TEM micrographs of each tissue were examined according to the 
criteria specified by the Hayat (1974) and investigated for the presence of gold nanoparticles.  
 
Colon tissue taken from inflamed regions is shown in Figure 3.7. Electron micrographs 
revealed collagen fibres (Cf) as seen in Figure 3.7.A. The inflamed colon tissue presented 
irregular shaped nuclei (N) with an intact nuclear membrane. Adjacent to the nuclear 
membrane, were dense chromatin masses as seen in Figure 3.7 (A, B, C). Cellular components 
were observed and are presumed to be mitochondria (Mi) (Figure 3.7.A, B), rough endoplasmic 
reticulum (RER) (Figure 3.7. B) and Golgi body (G) (Figure 3.7.C). To elaborate further, 
cellular objects labelled as mitochondria took on a circular outline, a common shape as reported 
by Grimstone (1968). However, this can only be presumed as their internal structure, cristae, 
could not be seen.  
Further staining procedures would be needed to confirm the above observation. The 
arrangement of layers/membranes with the appearance of granular material (ribosomes) 
attached were presumed to be rough endoplasmic reticulum (RER), see Figure 3.7.B. As seen 
in Figure 3.7.C, the Golgi body seen adjacent to the nucleus has been observed to be a large 
collection of membranous layers closely packed together, covered with ribosomes. According 
to Hayat’s criteria, a well preserved rough endoplasmic reticulum and Golgi body should 
appear to have flattened cristae, uniformly arranged and intact membranous layers with 
attached ribosomes. No gold nanoparticles were observed. 
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Figure 3.  7: TEM (BF) micrographs of colon tissue from inflamed regions of animals treated with AOM/DSS 
method 1, taken 24 hours after intravenous injection of AuNP-p.L. (Cf)- Collagen fibres, (N) Nuclei,  (RER) 
Rough endoplasmic reticulum, (Mi) Mitochondria and (G) Golgi body. 
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Tissue from the rectum is shown in Figure 3.8. Figure 3.8.A and B illustrate microvilli (Mv), 
interdigitations (I) and tight junction indicated by a black. Other subcellular constituents such 
as endoplasmic reticulum, Golgi body and lysosomes were not visible. No gold nanoparticles 
were observed. 
 
 
 
 
 
 
 
 
                          A 
 
 
 
 
 
 
 
                         B 
 
Figure 3.  8: TEM (BF) micrographs of rectum tissue of AOM/DSS method 1, taken 24 hours after intravenous 
injection of AuNP-p.L. (Mv) Microvilli, (I) Interdigitations and a tight junction (black arrow). 
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Pancreatic tissue is shown in Figure 3.9.A. Cellular components depicted in Figure 3.9.A, were 
presumed to be numerous zymogen granules (ZG) and smooth endoplasmic reticulum (SER). 
These cellular components corresponded to cellular components reported by Kitagawa and Ono 
(1986). The zymogen granules were of irregular sizes whilst the smooth endoplasmic reticulum 
was seen as intact membranes unattached to ribosomes surrounding the zymogen granules. No 
gold nanoparticles were observed. 
 
 
 
 
 
 
 
 
                          A 
 
Figure 3.9: TEM (BF) micrograph of pancreatic tissue of animals treated with AOM/DSS method 1, taken 24 
hours after intravenous injection of AuNP-p.L. (ZG) Zymogen granules and (SER) Smooth endoplasmic 
reticulum. 
 
Kidney tissue is shown in Figure 3.10. Cellular components depicted in Figure 3.10.A, revealed 
numerous densely packed, long mitochondria (Mi) orientated vertically among a layer of basal 
membrane (BM) and an intact nuclear membrane. These cellular components corresponded to 
the ultrastructural detail reported by Verlander (1998). 
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Figure 3.10: TEM (BF) micrographs of kidney tissue of animals treated with AOM/DSS method 1, taken 24 hours 
after intravenous injection of AuNP-p.L. (N) Nucleus, (Mi) Mitochondria and (BM) Basal membrane. 
 
Healthy liver tissue treated with AuNP-p.14 from group 5 is shown in Figure 3.11. Cellular 
components depicted in Figure 3.11.A, are likely to be rough endoplasmic reticulum (RER) 
and numerous irregular shaped mitochondria (Mi) showing intact cristae. A tight junction can 
be observed as indicated by two black arrows. These cellular components are based on similar 
ultrastructural studies reported by Kühnel (2003). The evaluation of Figure 3.11.B and C 
revealed the presence of electron-dense particles in cytoplasmic background surrounding 
mitochondria, as indicated by one black arrow. High resolution images as seen in micrograph 
B and C assisted in further characterizing the structure of the electron dense particles. However, 
resolution of particles could not be further resolved as seen in Figure 3.11.C. In order to 
elucidate the identity of these structures, additional TEM studies were performed with energy-
dispersive-X-ray (EDS) spectrum analysis. These structures could not be identified by EDS 
spectrum analysis to contain gold. EDX spectrum results not shown. 
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Figure 3.11: TEM (BF) micrographs of healthy liver tissue from group 5, taken  24 hours after intravenous 
injection of AuNP-p.14. (RER) Rough endoplasmic reticulum, (Mi) Mitochondria and Tight junction (two black 
arrows). At higher magnification, electron dense particles indicated by single black arrow. 
Healthy kidney tissue treated with AuNP-p.C from group 4 is shown in Figure 3.12. The bright 
field micrograph seen in Figure 3.12.A indicated the presence of electron-dense particles.  A 
high angle annular dark field image (HAADF) was recorded with the scanning transmission 
electron (STEM) microscope as seen in Figure 3.12.B. This technique is highly sensitive to 
atomic mass. A bright contrast is indicative of elements with higher density such as metals.  
However this technique does not efficiently confirm the presence of gold elements (Kempen 
et al., 2013). EDS spectroscopy identified the presence of gold. EDS spectrum results not 
shown. 
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                         B 
Figure 3.12:  TEM (A) BF and (B) High angle annular dark field (HAADF) micrograph of heathy kidney from  
group 4, taken 24 hours after intravenous injection of AuNP-p.C. 
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3.3.3. Discussion  
 
Most rodents, including rats, do not spontaneously develop colorectal cancer and are therefore 
predominantly used as a colorectal cancer model (Corpet & Pierre, 2005). When using single 
or multiple injections of AOM, colon tumour development has shown a low tumour incidence 
with a 7 to 9 month latency period (Neufert et al., 2007; Tanaka et al., 2003). However, with 
the follow-up treatment of DSS, tumour development could take as little as 7 to 10 weeks 
(Thaker et al., 2012). The objective of this study was first to establish and optimize a colorectal 
cancer rat model for the investigation of specific targeting and localization of peptide-gold 
nanoparticle conjugates (AuNPs-p.C, p.L and p.14) towards colorectal cancer tumours. This 
study was the first CRC induction to be investigated in our laboratory.  
 
Between the two models investigated (AOM/DSS method 1 and AOM/DSS method 2), 
histopathological findings suggested suspected lesions identified from AOM/DSS method 1 
protocol were inflamed and were not neoplastic contrary to findings of Thaker et al. (2012). 
The methods applied in this study therefore failed to induce colonic neoplasms in the rat model. 
Due to time constraints of this project and the high cost in the development of inducing 
colorectal cancer in rats, the animals given the AOM/DSS treatment were subjected to the 
AuNP/peptide treatment before they were to be sacrificed. When CRC was not observed in any 
AOM/DSS treated rats, results were interpreted to reflect a situation where nanoparticles have 
been injected for screening purposes. This study suggests that AuNP conjugated with the 
peptides used in this study will not give false negatives. 
 
Rats given DSS have been shown to either develop acute or chronic colitis (Perše & Cerar, 
2012). Chronic inflammation through long term DSS administration was shown to hasten the 
development of colonic malignancies. It has been stated that the relative weight loss is a 
surrogate measure of severity of colitis (Thaker et al., 2012). As depicted in Figure 3.4, 
throughout the AOM/DSS treatment, the control group (group 6, n=5) showed a higher average 
body weight than the group 1 (AOM/DSS method 1, n=6) but the difference was not significant 
until the day of AuNP treatment (P=0.0176). No significant difference in body weight between 
control group (group 6, n=5) and group 2 and 3 (AOM/DSS method 2, n=6) were observed, as 
seen in Figure 3.6. Apart from no significant weight loss, other symptoms of colitis severity 
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include a bloody stool and diarrhoea. These symptoms were not observed in the three 
experimental (group 1, group 2 and group 3) in this study. 
 
Although some researchers have administered multiple injections of AOM to induce CRC, this 
study could not prove that the two treatments of AOM benefit CRC development more than 
the one treatment. This study rather suggests that AOM increases the chances of DNA 
modification whilst the severity of inflammation following the initiation determines the 
development of CRC. It seems as if the severity of the inflammation is determined by the 
molecular weight of the DSS. Therefore, in future it seems to be important that DSS with a 
higher molecular weight of 40-50 kDa needs to be used. According to Perše and Cerar (2012) 
tumour promoting effects of DSS is said to be influenced by various factors, which include the 
DSS administration and duration, manufacturer, animal species and microbiota. Research 
findings conducted by Suzuki et al. (2005) has shown that the tumour promoting effect of DSS 
is dose-dependent. The use of a DSS dosage above 1% contributed to an increase in 
inflammation of the colon resulting in the increase incidence of tumours. However, the tumour 
promoting role of DSS was not specified in regards to the various molecular weights of DSS.  
 
According to the results of this study it also appears that, in the case of a minor inflammation, 
the body may develop a mechanism to combat the inflammation which may be the reason why 
there was no inflammation found in the rectum area of the rats in groups 2 and 3 (AOM method 
2). The mechanism in which DSS works is still under investigation. A possible suggestion to 
the non-occurrence of inflammation within group 2 and 3 (AOM/DSS method 1) could be 
bacterial bioactivity capable of improving colonic damage. This is just a suggestion and can be 
investigated at a later stage in another study, using the tissues that were collected in this study.  
 
In this study, all specified tissues (see section 2.6.6) were prepared for TEM visualization. Due 
to practical constraints not all tissue could be analysed. Tissue taken from control groups, group 
1 (inflamed colon tissue, rectum, pancreas and kidney), group 5 (liver) and group 4 (kidney) 
were further analysed by HRTEM (see Figure 2.2). 
 
Due to the unsuccessful induction of colorectal cancer, all experimental groups represent non-
colorectal tumour animal models. This can provide us with the necessary information regarding 
the distribution/accumulation of nanoparticles in healthy tissues and organs. This study has 
evaluated the presence of gold nanoparticles in group 1 and 5 and has found no accumulation 
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of AuNP-p.L and AuNP-p.14, respectfully. This suggests that these nanoparticles are unable 
to target to healthy tissues. The accumulation/biodistribution of AuNP-p.C in the kidney of 
experimental group 4 suggests that the AuNP-p.C does not bind to healthy tissues and as a 
result have been cleared by the kidneys in the absence of a ligand which should be present if 
cancer was induced.  For any diagnostic or therapeutic application, the absence of nanoparticles 
in healthy tissue and the removal of nanoparticles by renal clearance is preferred as this would 
imply that the AuNP/peptide conjugates exhibits a “ safe behaviour” (Alric et al., 2013). 
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CHAPTER FOUR: CONCLUSION AND FUTURE 
DIRECTIONS 
4.1. Conclusion 
 
Colorectal cancer (CRC) is the third most common cause of cancer-related deaths worldwide. 
Early colorectal cancer diagnosis is vital in reducing incidence and mortality. However, there 
is a need for the development of sensitive, specific and non-invasive screening tools for 
enhancing the detection of the disease. Complementing the knowledge of disease biomarkers, 
biomarker targeting molecules and nanotechnology can create a powerful diagnostic platform. 
Nanomaterials like gold nanoparticles have stimulated much interest in cancer research due to 
their unique physicochemical characteristics. Numerous studies have investigated the 
physicochemical characteristics (i.e. shape, surface charge, surface functionalization, 
concentration etc.) of these nanomaterials. However, a limited number of studies have dealt 
with their uptake and localization within cells and tissue utilizing HRTEM. This is an essential 
tool in understanding the interaction of all nanomaterials in an in vitro and in vivo model. 
The aim of this dissertation was to investigate the uptake and localization of three 
AuNP/peptide conjugates (AuNP-p.C, AuNP-p.14 and AuNP-p.L) in an in vitro and in vivo 
CRC model using HRTEM. In this study we employed 14 ± 3 nm colloidal gold nanoparticles 
synthesized by Mintek (Randburg, South Africa) and attached respectfully to the three peptides 
(p.C, p.L and p.14) by Minpeptide (Randburg, South Africa). TEM micrographs confirmed the 
size and morphology of the AuNPs. The size and surface charge of the peptide-gold 
nanoparticle conjugates in solution were further characterized by DLS and zeta potential. These 
techniques verified that the spherical AuNPs were uniform in size and morphology and were 
attached to their respective peptides. The nanoparticle solutions were also found to be stable in 
dispersion. 
In the present study, peptide-gold nanoparticle conjugates (AuNP-p.C, p.L and p.14) were 
investigated to achieve localization within cancer cell line (HT-29, Caco-2 and C3A). The cell 
sample underwent TEM preparation, which included sample washing, fixation, dehydration, 
and embedding. However, ultrastructural detail revealed signs of morphological alterations, 
which included changes in cell volume, subcellular organelle distortion, cellular leaking and 
plasma membrane disruption. Here, we were unable to demonstrate the localization of AuNPs 
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as a result of these findings. After studying the effects of the fixative and TEM preparation on 
the cell ultrastructure, we have identified additional steps and considered a different approach 
towards the handling of the biological samples for electron microscopy. In future, the in situ 
fixation approach, a low centrifugal force, the pH and osmolarity of fixative will be further 
investigated to avoid ultrastructural damage. It is possible that the omission of the post-fixation 
stage using heavy metals such as osmium tetroxide could have played a part in the preservation 
of cells. This will need to be investigated further. We can conclude that the findings of this 
study require modifications which would facilitate the selection of the best method to use for 
nanoparticle cell interactions. 
An objective of this study was to establish a colorectal cancer rat model for the investigation 
of specific binding and localization of AuNP/peptide conjugates (AuNPs-p.C, p.L and p.14) 
towards colorectal cancer tumours. This study was the first to be investigated in our laboratory 
and could not address this objective. Despite this, the non-colorectal cancer animal models 
provided an insight into the distribution of AuNP/peptide conjugates in healthy tissue and 
organs. The optimization of a CRC animal model will be approached again in the future. Future 
research should use a DSS molecular weight of 40 kD. The type of food, source of DSS and 
susceptibility of animal model will be looked into as this could affect the severity of colitis and 
the induction of tumours. Overall, TEM preparations of chosen tissue samples were of adequate 
standard. 
We presented an alternative approach to the preservation and visualization of TEM studies by 
omitting the post-fixation and staining of heavy metals. The results obtained surprisingly 
provided adequate contrast. However, in light of the aims of this study, the ability to determine 
the localization of AuNPs in different cellular compartments is essential. To obtain better 
quality preservation and contrast of cellular components, heavy metal fixation /staining would 
be necessary. Collectively, results suggest further research on electron microscopy cell/tissue 
preparation and the induction of colorectal cancer is warranted.  
In conclusion, with the increase in nanomaterial research and production, research involving 
transmission electron microscopy exposes the nanoparticle localization and their interaction 
with other biological entities. This is an essential task needed to be performed, specifically for 
future medical applications in targeted diagnostics and drug delivery. 
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4.2. Recommendations for future work 
 
In future, HRTEM results can be further validated by evaluating the biodistribution of gold in 
various organs using inductively coupled plasma mass spectrometry (ICP-MS). This technique 
gives an elemental analysis and therefore estimates the concentration of gold in each sample. 
 The following study presented an alternative approach to the preservation and visualization of 
TEM studies by omitting the post-fixation and staining of heavy metals. Although adequate 
contrast was achieved; unstained specimens require a low electron dose as a higher dosage 
could result in specimen damage. However this leads to a poor signal-to-noise ratio and noisy 
images. One of the ways that this could be improved would be cryo-electron microscopy. 
Imaging specimens at low ambient temperatures have been shown to reduce election damage 
as much as 6 fold compared to room temperatures. For future research, this would mean better 
imaging with a higher electron dosage.  
4.3. Limitations 
 
This study created awareness to various difficulties and limitations when using electron 
microscopy. The latter technique is the best for providing the necessary spatial resolution to 
visualize individual nanoparticles. However, this is a very time consuming (cell fixation, 
dehydration, resin embedding, TEM analysis) and low throughput process. This technique 
requires numerous images to be taken from a number of ultrathin sections to obtain significant 
results. TEM also requires the identification of nanoparticles from a small analysis volume 
which suggests that this technique is not suitable in determining the biodistribution of gold but 
would be adequate for determining the localization of gold within various tissue types. It can 
be suggested that TEM together with ICP-MS be used as complimentary tools in determining 
the systemic distribution and localization of gold within tissue 
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